US20180057791A1 - Methods and kits for cell activation - Google Patents
Methods and kits for cell activation Download PDFInfo
- Publication number
- US20180057791A1 US20180057791A1 US15/245,584 US201615245584A US2018057791A1 US 20180057791 A1 US20180057791 A1 US 20180057791A1 US 201615245584 A US201615245584 A US 201615245584A US 2018057791 A1 US2018057791 A1 US 2018057791A1
- Authority
- US
- United States
- Prior art keywords
- cell
- cells
- nucleic acid
- antibody
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 48
- 230000020411 cell activation Effects 0.000 title description 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 133
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 67
- 239000011230 binding agent Substances 0.000 claims abstract description 51
- 229940126530 T cell activator Drugs 0.000 claims abstract description 32
- 230000003213 activating effect Effects 0.000 claims abstract description 14
- 150000007523 nucleic acids Chemical group 0.000 claims description 72
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 54
- 108091034117 Oligonucleotide Proteins 0.000 claims description 50
- 108020004707 nucleic acids Proteins 0.000 claims description 32
- 102000039446 nucleic acids Human genes 0.000 claims description 32
- 229920000642 polymer Polymers 0.000 claims description 30
- 230000000295 complement effect Effects 0.000 claims description 19
- 230000003321 amplification Effects 0.000 claims description 13
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 13
- 239000013598 vector Substances 0.000 claims description 13
- 239000006143 cell culture medium Substances 0.000 claims description 9
- 238000005096 rolling process Methods 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 7
- 101710163270 Nuclease Proteins 0.000 claims description 3
- 241001663880 Gammaretrovirus Species 0.000 claims 1
- 241000713666 Lentivirus Species 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 76
- 230000004913 activation Effects 0.000 description 36
- 230000006044 T cell activation Effects 0.000 description 35
- 239000000047 product Substances 0.000 description 35
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 26
- 238000007792 addition Methods 0.000 description 25
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 24
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 24
- 125000003729 nucleotide group Chemical group 0.000 description 23
- 230000010261 cell growth Effects 0.000 description 20
- 239000002773 nucleotide Substances 0.000 description 20
- 108020004414 DNA Proteins 0.000 description 19
- 108020003175 receptors Proteins 0.000 description 18
- 102000005962 receptors Human genes 0.000 description 18
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 15
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 15
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 14
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 239000011324 bead Substances 0.000 description 9
- 238000000684 flow cytometry Methods 0.000 description 9
- 125000000129 anionic group Chemical group 0.000 description 8
- 125000002091 cationic group Chemical group 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000011065 in-situ storage Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000011534 incubation Methods 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000012190 activator Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 230000021615 conjugation Effects 0.000 description 6
- 230000000593 degrading effect Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 108091008874 T cell receptors Proteins 0.000 description 5
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 229940127121 immunoconjugate Drugs 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- 102100027207 CD27 antigen Human genes 0.000 description 4
- 239000007995 HEPES buffer Substances 0.000 description 4
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000001542 size-exclusion chromatography Methods 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- -1 3′-OMe Chemical class 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 102000012410 DNA Ligases Human genes 0.000 description 3
- 108010061982 DNA Ligases Proteins 0.000 description 3
- 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 description 3
- 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 description 3
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 3
- 102100033467 L-selectin Human genes 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000002659 cell therapy Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000003292 diminished effect Effects 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 108091023037 Aptamer Proteins 0.000 description 2
- 101001007348 Arachis hypogaea Galactose-binding lectin Proteins 0.000 description 2
- 108091029523 CpG island Proteins 0.000 description 2
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 2
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 2
- 102000003812 Interleukin-15 Human genes 0.000 description 2
- 108090000172 Interleukin-15 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 102000003923 Protein Kinase C Human genes 0.000 description 2
- 108090000315 Protein Kinase C Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 2
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 238000012436 analytical size exclusion chromatography Methods 0.000 description 2
- 229920006318 anionic polymer Polymers 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229920006317 cationic polymer Polymers 0.000 description 2
- 230000006727 cell loss Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 108091008034 costimulatory receptors Proteins 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 2
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229960003085 meticillin Drugs 0.000 description 2
- 108091005601 modified peptides Proteins 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- ATGUDZODTABURZ-UHFFFAOYSA-N thiolan-2-ylideneazanium;chloride Chemical compound Cl.N=C1CCCS1 ATGUDZODTABURZ-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- XFKSLINPMJIYFX-UHFFFAOYSA-N 1-sulfanylpyrrole-2,5-dione Chemical compound SN1C(=O)C=CC1=O XFKSLINPMJIYFX-UHFFFAOYSA-N 0.000 description 1
- NZGSNQJCTOMELT-UHFFFAOYSA-N 3,5-dimethylorsellinic acid Chemical compound CC1=C(C)C(C(O)=O)=C(O)C(C)=C1O NZGSNQJCTOMELT-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 108091028732 Concatemer Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 238000005698 Diels-Alder reaction Methods 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
- 101001024703 Homo sapiens Nck-associated protein 5 Proteins 0.000 description 1
- 101150083678 IL2 gene Proteins 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 101100508567 Mus musculus Il7 gene Proteins 0.000 description 1
- 102100036946 Nck-associated protein 5 Human genes 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- CESGKXMBHGUQTB-VONOSFMSSA-N [(1S,2S,6R,10S,11R,13S,14R,15R)-1,6,14-trihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxo-13-tetracyclo[8.5.0.02,6.011,13]pentadeca-3,8-dienyl] tetradecanoate Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(OC(=O)CCCCCCCCCCCCC)C(C)(C)[C@H]3[C@@H]21 CESGKXMBHGUQTB-VONOSFMSSA-N 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000005600 alkyl phosphonate group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 238000011130 autologous cell therapy Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 238000005422 blasting Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000003710 calcium ionophore Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000012612 commercial material Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- CJAONIOAQZUHPN-KKLWWLSJSA-N ethyl 12-[[2-[(2r,3r)-3-[2-[(12-ethoxy-12-oxododecyl)-methylamino]-2-oxoethoxy]butan-2-yl]oxyacetyl]-methylamino]dodecanoate Chemical compound CCOC(=O)CCCCCCCCCCCN(C)C(=O)CO[C@H](C)[C@@H](C)OCC(=O)N(C)CCCCCCCCCCCC(=O)OCC CJAONIOAQZUHPN-KKLWWLSJSA-N 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 238000005206 flow analysis Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 125000001245 hexylamino group Chemical group [H]N([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 229940100994 interleukin-7 Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000033667 organ regeneration Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 238000011338 personalized therapy Methods 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical group NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 108010064470 polyaspartate Proteins 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000003906 pulsed field gel electrophoresis Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000012090 serum-supplement Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- YLHGDRHEIJPKLL-UHFFFAOYSA-N thiolan-2-amine;hydrochloride Chemical compound Cl.NC1CCCS1 YLHGDRHEIJPKLL-UHFFFAOYSA-N 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
Definitions
- T cell therapies in particular, have shown remarkable success in treating hematological tumors and show promise in the treatment of solid tumors. These treatments require isolation of a patient's PBMC's or T cells and subsequent expansion (activation and proliferation) to generate a personalized therapeutic dose.
- this type of personalized therapy consists of removing blood cells from cancer patients; isolating and activating T cells; genetically modifying the T cells thereby programming those cells to recognize and attack cancer cells; expanding the T cells; and, lastly, introducing those cells back into the body so the patient's immune system can take over.
- Activation is a critical component of the whole process as it is required for efficient introduction of genetic material and for robust expansion.
- T cells comprising providing a population of T cells, adding a plurality of first agents, wherein the first agent comprises a T-cell activator and a first binder moiety; adding a second agent comprising a plurality of capture oligomers, wherein at least a segment of at least one of the plurality of capture oligomers is capable of associating with the first binder moiety; and incubating the population of T cells after steps (b) and (c), whereby at least a portion of the population of T cells is activated.
- the method may further comprise the addition of a T-cell co-stimulator.
- the present invention is a method for activating T cells, the method comprising providing a population of T cells, adding a plurality of first agents, wherein the first agent comprises a T-cell activator attached to a nucleic acid sequence; adding a nucleic acid polymer comprising a plurality of capture oligonucleotides, wherein at least a segment of at least one of the plurality of capture oligonucleotides is capable of associating with the nucleic acid sequence; and incubating the population of T cells after steps (b) and (c), whereby at least a portion of the population of T cells is activated.
- the method may further comprise the addition of a T-cell co-stimulator.
- the T-cell co-stimulator is attached to a nucleic acid sequence, wherein at least a segment of at least one of the plurality of capture oligonucleotides is capable of associating with the nucleic acid sequence attached to the T-cell co-stimulator.
- the present invention relates to a kit comprising a T cell activator attached to a nucleic acid sequence; and a nucleic acid polymer comprising a plurality of capture oligonucleotide sequences, wherein the nucleic acid sequence is complementary to at least a segment of at least one of the capture oligonucleotide sequences.
- FIG. 1A-1E are representative flow cytometry histograms for positively validated anti-CD3-o20b(+)act and anti-CD28-o20b(+)act conjugates binding to T cells.
- 1 A Binding of a DNA (o20b(+)act) attached anti-CD28 antibody to T cells
- 1 B Binding of corresponding unconjugated anti-CD28 antibody (positive control)
- 1 C Binding of a DNA (o20b(+)act) attached anti-CD3 antibody to T cells
- 1 D Binding of corresponding unconjugated anti-CD3 antibody (positive control)
- 1 E Cell incubated with labeled secondary antibody (negative control).
- FIG. 2 is an illustration of the preparation of single stranded rolling circle amplification (ssRCA) to produce RCA products (RCAact) for T cell activation in two steps.
- ssRCA single stranded rolling circle amplification
- FIG. 3A is graphical representation of T cell activation measured as population of cells expressing CD25 receptor (a marker of T cell activation) by DBTA (DNA-Based T cell Activation) relative to the CD3/CD28 Dynabeads benchmark with respect to both early (days 1 and 4) % CD25 expression. Also shown are various controls including unconjugated antibodies alone and cells alone (without activator) not expected to cause significant activation.
- FIG. 3B is a graphical representation of the same cultures as in FIG. 3A at days 4 and 7 showing cell expansion represented as number of folds of expansion relative to starting count (cell counts).
- FIG. 4A is a graphical representation showing significant activation (relative to control) achieved with different DBTA systems, a DBTA system wherein only the anti-CD3 antibody is attached to the o20b(+)act (anti-CD3-o20b(+)act) and another DBTA system wherein both anti-CD3 and anti-CD28 are attached to o20b(+)act. Measured is the % CD25 expression.
- FIG. 4B is a graphical representation of the same cultures as FIG. 4A after 4 and 7 days showing x-fold expansion (cell counts) as in FIG. 3B .
- FIG. 5A is a graphical representation showing a trend towards higher activation when the DBTA components are mixed in situ compared to when they are pre-incubated/pre-associated and then mixed with cells.
- FIG. 5B is the same cultures as FIG. 5A after 4 days showing x-fold expansion (cell counts).
- FIG. 6A is a graphical representation showing T cell activation (24-hour % CD25) under a variety of conditions including different ratios of anti-CD3-DNA and anti-CD28-DNA with same RCA amount (10 RCA repeat units/per anti-CD3-DNA conjugate) and different amounts of DBTA reagent while keeping the ratio of anti-CD3-DNA conjugate and RCA repeat unit constant at 1:10.
- FIG. 6B is a graphical representation of cell expression of the same cultures as FIG. 6A after days 4 and 7 showing x-fold expansion (cell counts).
- FIG. 7A is a graphical representation of greater than two-fold lower early activation (24-hour % CD25 expression) for sample where cells were pre-mixed with anti-CD3 and anti-CD28 DNA conjugates for 30 minutes prior to adding RCA compared to all three DTBA components added at once (one after another).
- FIG. 7B is a graphical representation of the same cultures as FIG. 7A showing diminished day 7 cell expansion (x-fold expansion, cell counts).
- FIG. 8A is a graphical representation showing T cell activation (% CD25 expression) is achieved for both CpG and no CpG RCA at different ratios (1:1, 1:10 and 1:100) of the anti-CD3-DNA:RCAact.
- FIG. 8B is a graphical representation of the same cultures as FIG. 8A showing x-fold expansion (cell counts) after 4 and 7 days.
- FIG. 9A is a graphical representation showing T cell activation with a different DNA sequence (a portion of MRSA (Methicillin-resistant Staphylococcus aureus ) sequence) attached to the anti-CD3 antibody and its complementary RCA product.
- MRSA Metal-resistant Staphylococcus aureus
- FIG. 9A is a graphical representation of the same cultures in FIG. 9A showing x-fold cell expansion after days 4 and 7.
- FIG. 10A is a graphical representation showing that the larger the RCA product, the higher the activation (% CD25 expression).
- FIG. 10B is a graphical representation of the same cultures in FIG. 10A showing higher x-fold expansion (cell counts) with larger product in early expansion phase (day 4), however, by day 7 all the three RCA products of different sizes yield comparable levels of cell expansion.
- While certain embodiments are directed towards autologous cell therapies that involve collection, manipulation, and re-insertion of a patient's own cells, the applications of the disclosed techniques may include allogenic cells, modified human cells, or xenotransplantation of non-human cells.
- Cell based therapies that are contemplated as being used in conjunction with the disclosed techniques may include therapies for organ or tissue regeneration, cancer treatment, blood disorders, immunotherapies, heart disease, or any other cell-based therapies.
- a variety of cell types may be utilized within the context of the present invention including for example, but not limited to, cell types such as B cells, T-cells, or natural killer cells.
- the cells can be isolated from any tissue such as peripheral blood, bone marrow, or tumor tissue.
- Some embodiments are directed towards T cells enriched from peripheral blood by centrifugation using for example Ficoll-PaqueTM or PercollTM (GE Healthcare) gradient. Some other embodiments are directed towards a specific subpopulation of T-cells, such as CD28+, CD4+, CD8+, CD45RA+, and/or CD45RO+ T cells, further isolated by positive or negative selection techniques.
- second agent refers to a polymer comprising a plurality of capture oligomers, wherein at least a segment of at least one of the plurality of capture oligomers is capable of associating with a first binder moiety.
- the second agent is a nucleic acid polymer such as a rolling circle amplification product and the “capture oligomer” is a capture oligonucleotide sequence.
- the nucleic acid polymer may comprise a plurality of the same or different capture oligonucleotide sequences.
- the number of capture oligonucleotide sequences in the nucleic acid polymer is greater than 3, preferably greater than 30, and more preferably greater than 300.
- the number of capture oligonucleotide sequences is greater than 2000.
- the nucleic acid polymer may comprise a plurality of capture oligonucleotide sequences of the same or different nucleotide sequence, molecular weights, geometrical arrangements, and/or patterns of repetition.
- the capture oligonucleotide sequence may have a length in range of from about 6 nucleotides to about 12 nucleotides, from about 12 nucleotides to about 25 nucleotides, from about 25 nucleotides to about 50 nucleotides, from about 50 nucleotides to about 100 nucleotides, from about 100 nucleotides to about 250 nucleotides, or from about 250 nucleotides to about 500 nucleotides.
- the second agent is double-stranded nucleic acid polymer while in other embodiments it is a single-stranded nucleic acid polymer.
- the nucleic acid polymer may include natural or unnatural nucleotides with modifications on the nucleic acid base, sugar or phosphate backbone.
- the second agent may further comprise spacer oligonucleotide sequences having different number and/or sequence of nucleotides than the capture oligonucleotide sequences, or non-nucleic acid spacer molecules.
- the second agent is a cationic polymer comprising a plurality of capture cationic oligomers, containing contiguous stretches of cationic monomers such as histidine or lysine.
- the second agent may further comprise neutral or anionic spacer residues provided the overall charge remains cationic.
- the second agent is an anionic polymer comprising a plurality of capture anionic oligomers, containing contiguous stretches of anionic monomers such as acrylate.
- the second agent may further comprise neutral or cationic spacer residues provided the overall charge is anionic.
- first agent refers to a cell activator attached to a “first binder moiety”.
- the cell activator is a T-cell activator.
- first binder moiety refers to a molecule that can associate with one or more capture oligomers.
- the first binder moiety is a nucleic acid sequence and the “second agent” is a nucleic acid polymer comprising a plurality of capture oligonucleotide sequences, such that the nucleic acid sequence of the first binder moiety is complementary to at least a segment of at least one of the plurality of capture oligonucleotide sequences.
- the nucleic acid sequence of the first binder moiety and the capture oligonucleotide sequence are capable of associating via complementary base-pair hybridization.
- the first binder moiety and the capture oligonucleotide may hybridize to form a double or triple helix structure depending on whether the nucleic acid polymer is a double-stranded nucleic acid polymer or a single-stranded nucleic acid polymer.
- all the nucleotide residues of at least one capture oligonucleotide sequence may hybridize to complementary nucleotides in the first binder moiety.
- At least one capture oligonucleotide sequence may have 50 nucleotide residues and all the 50 nucleotide residues may hybridize to complementary nucleotides in the first binder moiety.
- all the nucleotides of the capture oligonucleotide sequence may not have corresponding complementary nucleotides in the nucleic acid sequence of the first binder moiety.
- the capture oligonucleotide sequence and/or the nucleic acid sequence of the first binder moiety may include nucleic acid analogs, with modified bases such as azidothymidine, inosine, or uridine, or modified sugars, e.g. 3′-OMe, or modified backbone, e.g. phosphorothioate, alkylphosphonate, phosphoramidate backbones.
- the first or second agent may further comprise non-complementary spacer oligonucleotide sequences or non-nucleic acid spacer molecules.
- the first binder moiety is an anionic moiety such as a nucleic acid sequence, alginate, polyglutamate, polyaspartate or hyaluronate and the second agent is a polymer comprising a plurality of cationic capture oligomers.
- the anionic first binder moiety is capable of associating with at least a segment of at least one of the plurality of cationic capture oligomers via electrostatic association.
- the first binder moiety is a cationic moiety and the second agent is a polymer comprising a plurality of anionic capture oligomers.
- T-cell activator refers any agent that can activate a T-cell for proliferation and/or transduction.
- suitable examples of T-cell activator include small organic molecules (for example ionomycin, phorbol myristate or acetate), natural or modified peptides, proteins (for example antibodies or affibodies), non-natural peptide mimics, nucleic acids (for example polynucleotides, PNA, DNA, RNA or aptamers), polysaccharides (for example lectins or sugars), lipids, enzymes, enzyme substrates or inhibitors, ligands, receptors, antigens, or haptens.
- small organic molecules for example ionomycin, phorbol myristate or acetate
- natural or modified peptides for example antibodies or affibodies
- non-natural peptide mimics for example nucleic acids (for example polynucleotides, PNA, DNA, RNA or aptamers), polysaccharides (for
- the T-cell activator binds to a T-cell surface receptor, such as a T-cell activating receptor, which results in delivery of a primary activation signal in a T-cell.
- T-cell activating receptors include for example T-Cell Receptor (TCR) or CD3 receptor.
- TCR T-Cell Receptor
- a primary activation signal can be initiated through binding between a TCR and an antigen presented in conjunction with either MHC class I or class II molecules, in order to stimulate an antigen-specific T-cell activation.
- a primary activation signal can also be initiated through binding between a CD3 receptor and a ligand targeted to the CD3 receptor, in order to stimulate a polyclonal T-cell activation.
- the T-cell activator is an anti-CD3 antibody or fragments thereof.
- T-cell activator include concanavalin A, protein kinase C (PKC) activator such as a phorbol ester (for example phorbol myristate acetate) or calcium ionophore (for example ionomycin which raises cytoplasmic calcium concentrations) and others.
- PLC protein kinase C
- a first agent that binds to a TCR or a CD3 receptor may be used in conjunction with other T-cell activators.
- the method of activating T cells comprises the addition of a plurality of a 1 st population of first agents, wherein all the first agents in the 1 st population of first agents comprises T-cell activator of the same type, such as an anti-CD3 antibody.
- the method may further comprise the addition of a 2 nd , 3 rd , . . . n th population of first agents.
- the T-cell activators among different populations of first agents may be of the same type or different types such as anti-CD3 antibodies or fragments thereof or antigens bound to MHC molecules.
- the method of activating T cells further comprises the addition of a T-cell co-stimulator.
- T-cell co-stimulators include ligands targeted towards T-cell co-stimulatory receptors such as CD28, CD2, ICOS, OX40, or 4-IBB receptors.
- Suitable ligands may include one or more of natural or modified peptides, proteins (for example antibodies, affibodies), non-natural peptide mimics, nucleic acids (for example polynucleotides, PNA, DNA, RNA, or aptamers), polysaccharides (for example lectins, sugars), lipids, enzymes, enzyme substrates or inhibitors, ligands, receptors, antigens, or haptens.
- the addition of a T-cell co-stimulator may include the addition of one or more types of T-cell co-stimulators. In some embodiments the T-cell co-stimulator may be attached to a second binder moiety.
- second binder moiety refers to a molecule that can associate with one or more capture oligomers.
- the second agent is a nucleic acid polymer and the second binder moiety is a nucleic acid sequence, which is same as or different from the nucleic acid sequence of the first binder moiety.
- the second agent is a cationic polymer and the second binder moiety is an anionic moiety.
- the second agent is an anionic polymer and the second binder moiety is a cationic moiety.
- a T-cell activator can be attached to a first binder moiety by any means provided the attachment does not interfere with the activator's ability to activate T cells.
- a T-cell co-stimulator can be attached to a second binder moiety by any means provided the attachment does not interfere with the co-stimulator's ability to provide a co-stimulatory signal to the T cell.
- the attachment may be covalent or noncovalent, electrostatic, or hydrophobic. In a preferred embodiment the attachment is covalent.
- the T-cell activator is an anti-CD3 antibody attached to a nucleic acid sequence
- the T-cell co-stimulator is an anti-CD28 antibody attached to a nucleic acid sequence
- the second agent is a rolling circle amplification product comprising a plurality of complementary capture oligonucleotide sequences.
- the first agent and the second agent are soluble in cell culture media.
- “cell culture media” refers to any standard T cell culture media, which are known in the art. Illustrative media include but are not limited to RPMI 1640, AIM-V, DMEM, MEM, ⁇ -MEM, F-12, X-Vivo 15.
- the T cell culture media may be serum-free or supplemented with serum, such as human serum or serum supplement.
- the T cell culture media is further supplemented with additional growth factors and cytokines such as interleukin-2 (Il-2), interleukin-7 (Il-7) or interleukin-15 (IL-15).
- situ generally refers to an event occurring in the original location, for example in the location where T cell activation occurs. In some embodiments “in situ” refers to an event happening in the T cell culture media under cell culturing condition.
- the invention includes embodiments that relate generally to methods of activating T cells for cellular therapy.
- the method includes the addition of a plurality of first agents, each first agent comprising a T-cell activator attached to a first binder moiety, wherein the T-cell activators are capable of binding to a set of T-cell surface receptors, such as the T-cell activating receptors, inducing a cellular event within the T cells that leads to activation and proliferation of the cells.
- a clustering of the T-cell surface receptors is induced by a second agent, which associates with the first binder moiety bringing the T-cell activators in proximity to each other.
- the method further includes the addition of a plurality of T-cell co-stimulators capable of binding to a different set of T-cell surface receptors, such as the T-cell co-stimulatory receptors.
- the T-cell co-stimulator may be attached to a second binder moiety.
- the second agent associates with both the first binder moiety and the second binder moiety thereby inducing a clustering of the T-cell surface receptors.
- the second agent is a nucleic acid polymer comprising a plurality of capture oligonucleotide sequences and the association is caused by base-pair hybridization between a nucleic acid sequence attached to the T-cell activator and a complementary capture oligonucleotide sequence.
- the method further comprises the addition of a T-cell co-stimulator attached to a second binder moiety, wherein the second binder moiety is also a nucleic acid sequence, and the nucleic acid sequence is capable of association with a complementary capture oligonucleotide sequence by base-pair hybridization.
- the association of the capture oligomer with the first binder moiety and the second binder moiety is caused by electrostatic interaction between oppositely charged species for example anionic moieties attached to the T-cell activator and T-cell co-stimulator with cationic capture oligomers or vice versa.
- the first agent, the second agent, and optionally a T-cell co-stimulator which may or may not be attached to a second binder moiety, are added simultaneously or sequentially in any order, to a population of T cells provided in a cell culture media, to allow an in-situ association.
- the first agent, the second agent, and optionally a T-cell co-stimulator attached to a second binder moiety are allowed to pre-incubate and associate to form a pre-associated complex. The pre-associated complex is then added to the population of T cells.
- the first agent, the second agent, and optionally the T-cell co-stimulator attached to a second binder moiety are allowed to associate in-situ.
- the T cells are incubated with the first agent, the second agent, and optionally a T-cell co-stimulator for a period of time, whereby at least a portion of the population of T cells is activated.
- the T-cell co-stimulator is attached to a second binder moiety.
- the time sufficient to activate a portion of the population of T cells may range from about 1 minute to about 14 days. In certain embodiments, the time may be from about 24 h to about 8 days. In some embodiments, at least 15% of T cells are activated. In preferred embodiments at least 25% of the T cells are activated, and in more preferred embodiment the majority of the T cells, greater than 50% are activated.
- the incubation may be done in a bioreactor having a controlled environment of temperature, humidity, CO2 concentration, for example at 37° C. and 5% CO2. In some embodiments the incubation may be done in a static bioreactor where there is no movement of the bioreactor, while in some other embodiments the incubation may be done in a bioreactor placed on a rocking platform.
- the invention provides methods to activate and selectively expand a specific subpopulation of T cells from a mixed population of T cells. This can be achieved for example by varying the nature or relative proportion of the T-cell activators and T-cell co-stimulators. Further, the invention provides methods to control T-cell surface receptor clustering and hence activation by adjusting for example the number of or distance among the T-cell activators and T-cell co-stimulators, which are associated with the second agent. In an exemplary embodiment where the second agent is a nucleic acid polymer, this can be achieved by precisely controlling the number and/or length of the capture oligonucleotides, or the length of the spacers.
- the expression of certain antibodies such as CD25 may be used to measure the activation of the T cells.
- the expression of CD25 receptors on the T cells may be assayed by labeled anti-CD25 antibodies to enumerate the labeled cells.
- activation may be measured by other markers signifying T-cell surface receptor clustering, which induces activation and expansion.
- the other markers used to measure T cell activation and expansion include CD4, CD8, CD27, CD28, CD3, CD57, CD25, and CD62L.
- the first agent and the second agents are bio-degradable.
- bio-degradable refers to materials that degrade in biological fluid. In some embodiments, the degradation may occur using chemical or enzymatic means.
- the method of activation of T cells further comprises the addition of a degrading enzyme such as a nuclease. In some embodiments the degrading enzyme, such as the nuclease, is added after at least a portion of the population of T cells is activated. In some embodiments, the degrading enzyme is added after the T cells have expanded at least 10-100 fold.
- the degrading enzyme is added at the end of the culture period, before the T cells are harvested from the cell culture media, prior to washing, concentration and final formulation. It should be noted that the degrading enzyme can be added any time after at least a portion of the population of T cells is activated and before the T cells are administered into a patient. In certain embodiments, after degradation, the degraded by-products of the first and second agents can be removed during washing and concentration of the T cells, and additional purification steps are not necessary. In some other embodiments, the second agent and the first agent are biocompatible and may be rapidly degraded in the blood stream. In such cases, the addition of a degrading enzyme may not be required before the T cells are administered into a patient.
- the use of such soluble, biodegradable systems are advantageous over polystyrene beads or other comparable bead based approaches since the use of such systems may avoid the need for additional purification steps, such as magnetic separation, which often leads to significant cell loss.
- the second binder moiety is also biodegradable.
- the method of T cell activation further comprises the addition of a vector comprising a foreign gene.
- the foreign gene encodes a chimeric antigen receptor or a T-cell receptor.
- the vector is a viral vector such as a ⁇ -retroviral vector or a lentiviral vector.
- the vector is a plasmid vector.
- the vector is added simultaneously with the first agent, while in some other embodiments, the vector is added after at least a portion of the population of T cells is activated.
- kits comprising a T-cell activator attached to a nucleic acid sequence, a nucleic acid polymer comprising a plurality of capture oligonucleotide sequences, and optionally a T-cell co-stimulator.
- the T-cell co-stimulator is attached to a nucleic acid sequence, which is same as or different from the nucleic acid sequence attached to the T-cell activator.
- the kit is a DNA-Based T cell Activation (DBTA) construct comprising a DNA polymer such as a rolling circle amplification product and one or more of the following components, i) a T-cell activator attached to a DNA sequence (first binder moiety), and ii) a T-cell co-stimulator attached to a DNA sequence (second binder moiety), which is same as or different from the DNA sequence attached to the T-cell activator.
- DBTA DNA-Based T cell Activation
- DNA-Based T cell Activation (DBTA) polymer constructs are representative nucleic acid polymer systems that initiate T cell clustering, activation, and subsequent expansion.
- DBTA comprises a DNA polymer produced via rolling circle amplification (such as RCAact) and consisting of repeating 43-base oligonucleotide segments and one or more of the following components: (1) anti-human CD3 monoclonal antibodies conjugated to 20-base DNA sequence derived from human beta-actin (o20b(+)act), (2) anti-human CD28 monoclonal antibodies also conjugated with DNA sequence o20b(+)act.
- the 43-base oligonucleotide segments bear full complementarity to the DNA sequences conjugated to the antibodies (1) and (2).
- the sequences of RCAact are derived from the complement to the RCA template sequences given below in Table 1:
- the starting nucleic acid sequence (prot-mal-o20b(+)act) is provided by TriLink Biotechnologies and comprises a 20-base DNA sequence capped with an N-terminal C6 spacer followed by a protected tricyclic maleimide moiety.
- a reactive mal-o20b(+)act derivative is generated via an inverse electron-demand Diels-Alder deprotection step, whereby the starting nucleic acid sequence is suspended in anhydrous toluene ( ⁇ 1 mg/mL) and heated at 90° C. for 4 h. Precipitation of the nucleic acid sequences via benchtop centrifugation and removal of solvent is followed by several washes (3 ⁇ 1 mL) with cold ethanol.
- the washed solid product Upon further reduction of residual organic solvents under reduced pressure, the washed solid product is dissolved in 100 mM HEPES buffer, pH 7.3 and the solution concentration is determined via UV-Vis spectroscopy (NanoDrop).
- the resulting stock solution (0.5-1 mM in DNA) or a portion thereof may be used directly for antibody conjugation with thiol-modified antibody.
- the remaining mal-o20b(+)act stock may be stored for several months at ⁇ 20° C. without significant loss of reactivity.
- a 10 mM stock solution of Traut's reagent (2-aminothiolane hydrochloride) is first prepared in 100 mM HEPES buffer, pH 7.3.
- a 1 mg/mL solution of anti-CD3 Ab (OKT3 clone, eBioscience) or anti-CD28 Ab (9.3 clone, GeneTex) in PBS is then mixed with both 20 ⁇ pH 8.5 borate buffer (ThermoFisher) and 10 mM Traut's reagent stock solution in a 8:1:1 ratio by volume.
- the resulting solution is thoroughly mixed and allowed to incubate at room temperature for 0.75 h.
- the unused portion of the Traut's mixture may be stored for several months at ⁇ 20° C.
- the reaction mixture is purified using a conventional desalting column (e.g. NAP-5 or PD-10, GE Healthcare Life Sciences) that has been equilibrated with 100 mM HEPES, pH 7.3 buffer.
- the collected fractions are then immediately analyzed by UV-Vis spectroscopy (NanoDrop).
- the resulting protein recovery at this stage is typically >60% for both anti-CD3 and anti-CD28 antibodies using known molar extinction coefficients for antibody at 280 nm.
- the volume of mal-o20b(+)act corresponding to a target molar input ratio of 10-40:1 o20b(+)act:Ab is added to an aliquot of freshly prepared, purified, thiol-activated Ab. After thorough mixing, the resulting solution is allowed to incubate at room temperature overnight (16-24 h).
- Final conjugate purification is achieved via selective precipitation of Ab using a saturated ammonium chloride solution. First, a volume of saturated ammonium chloride equal to the total reaction volume is added, thoroughly mixed, and placed on ice. After 15 min, the sample is centrifuged at 15,000 ⁇ g rcf for 10 min at 10° C.
- Example 1 To ensure that the Ab-DNA conjugates prepared in Example 1 retain their specific cell binding capabilities to T cells, validation studies are performed for each conjugate batch using flow cytometry (Cytoflex S, Beckman Coulter). NBP Pan T Cells (ALL Cells) are thawed at 37° C. in 10 mL warm complete media (see Example 4) and then centrifuged at 300 ⁇ g rcf for 10 min. Cells are then resuspended in 10 mL fresh complete media and analyzed on a Nucleocounter® NC-200 system to determine cell counts and viability. After adjusting the concentration to 1 ⁇ 10 6 cells/mL and washing with PBS, the T cells are then blocked in 10% Normal Goat Serum (NGS) in PBS at 4° C.
- NGS Normal Goat Serum
- anti-CD3-DNA and/or anti-CD28-DNA conjugate (anti-CD3-o20b(+)act and/or anti-CD28-o20b(+)act) test samples (Example 1) as well as unlabeled or unconjugated anti-CD3 and/or anti-CD28 Ab positive controls (Ab not attached to DNA) are used.
- FIG. 1A through 1E Representative flow cytometry histograms for positively validated anti-CD3-o20b(+)act and anti-CD28-o20b(+)act conjugates binding to T cells are shown in FIG. 1A through 1E ; Anti-CD28-o20b(+)act, anti-CD28 unlabeled, Anti-CD3o20b(+)act, anti-CD3 unlabeled, and FITC-labeled respectively.
- high percentage of anti-CD3+ and anti-CD28+ cell binding is observed (>85% for both).
- Preparation of single stranded rolling circle amplification (ssRCA) to produce RCA products (RCAact) for T cell activation comprises two steps: 1) ligation of a linear DNA strand to generate a circular template, and 2) amplification of the ligated circle to synthesize long single stranded concatemers.
- the ligation was accomplished using a high concentration of T4 DNA Ligase and its corresponding reaction buffer (New England Biolabs®) Two deoxyoligonucleotides (oligonucleotide) were present in the ligation.
- oligonucleotide oligonucleotide
- One oligonucleotide (RCAact-NoCG) consisted of 43 bases of the DNA sequence of the human ⁇ -actin gene and contained a 5′ phosphate group.
- This 43 base oligonucleotide would become the circular template following ligation.
- the second oligonucleotide was 20 bases in length (RCAact Primer) and was complimentary to both ends of the 43 base oligonucleotide. This second oligonucleotide was used to both form the circle prior to ligation and then amplify the circle in the subsequent ssRCA reaction (see FIG. 2 ).
- 450 pmol of the 43 base oligonucleotide were mixed in a 120 ⁇ L volume with 300 pmol of the 20 base oligonucleotide in an annealing buffer consisting of 10 mM Tris, pH 8, and 50 mM sodium chloride. The mixture was heated at 95° C.
- the ssRCA reaction was prepared by mixing 69.3 ⁇ L of the completed ligation reaction with 550 ⁇ L of 2 ⁇ Phi29 Reaction Buffer (100 mM HEPES Buffer, pH 8.0, 150 mM potassium chloride, 2 mM TCEP, 40 mM magnesium chloride, 0.02% (v/v) Tween 20, 5% (v/v) polyethylene glycol and 1.6 mM each dATP, dCTP, dGTP and dTTP) in a final volume of 1.078 mL. After mixing, amplification was started by the addition of 22 ⁇ L of 1 mg/ml Phi29 DNA polymerase. Amplification reactions were incubated at 30° C. for 18 hours and then 65° C.
- Phi29 Reaction Buffer 100 mM HEPES Buffer, pH 8.0, 150 mM potassium chloride, 2 mM TCEP, 40 mM magnesium chloride, 0.02% (v/v) Tween 20, 5% (
- RCAact products The apparent size of RCAact products is determined by pulse field gel electrophoresis relative to yeast ( S. cerevisiae ) or lambda DNA molecular weight ladders.
- gel-shift assays using non-denaturing agarose gels are used to confirm hybridization of anti-CD3-o20b(+)act and anti-CD28-o20b(+)act conjugates (Example 1) with RCAact.
- Example 4 Comparison of T Cell Activation and Expansion Using Dynabeads® Human T-Expander CD3/CD28 and a DBTA System of Nucleic Acid Polymers with Ab-DNA Conjugates (Anti-CD3-DNA and Anti-CD28-DNA)
- Pan T Cells Frozen aliquots of human Pan T Cells from AllCells (Catalog# PB009-IF) are used for all activation and expansion studies. Pan T Cells are thawed and processed as described in Example 2 and added to following complete X-Vivo media to give an initial concentration of 1 ⁇ 106 cells/mL as shown in Table 2.
- Typical activation and expansion experiments are performed in a 6-well format using a 2 mL seeding volume per well with a minimum of one additional replicate per condition tested.
- Dynabeads® Human T-Expander CD3/CD28 (Catalog#111.41D, ThermoFisher) are prepared according to the manufacturer's instructions. Briefly, a bead aliquot is washed with 0.3 mL complete media three times, with supernatant wash removal occurring after sample application to DynaMag-2 permanent magnet (ThermoFisher). After resuspension in complete media, a 60 bead slurry aliquot is added per well such that an approximate 3:1 bead-to-cell ratio is used for initial activation conditions (starting with 2 ⁇ 10 6 total cells per well).
- DBTA components Ab-DNA and RCAact
- aliquots of DBTA components are added separately and consecutively to cells directly from their respective stock solutions (stored at 4° C.). Additions of each DBTA component may be made in any sequential order.
- Standard initial concentrations of DBTA components are as follows: 1 ⁇ g/mL (6.7 nM) each for anti-CD3-o20b(+)act (anti-CD3-DNA) and anti-CD28-o20b(+)act (anti-CD28-DNA) with 10-fold molar excess of RCAact ( ⁇ 67 nM).
- RCAact concentration is based on the molar concentration of the repeating 43-base segment and independent of total RCA product length or polydispersity.
- the well contents are mixed with a 1 mL pipette.
- the plates are then incubated at 37° C. and 5% CO2 atmosphere under static conditions for 1-7 days or longer with periodic aliquots taken and, dilutions done with fresh media as needed for continuing expansion and analysis. Confirmation of cell activation is achieved by % CD25 expression using flow cytometry after 24 h incubation (day 1) and followed by additional measurements, if needed, at days 4 and 7. Cell counts, viability, and size (blasting) are additionally measured at days 4 and 7 using the Nucleocounter.
- a 1:4 or 1:8 dilutions with fresh complete media is performed to reduce cell density to 250,000 cells/mL per well. This enables cells to expand in the exponential phase, without overgrowth, until day 7 analysis.
- cell density is maintained at a minimum of 500,000 cells/mL. Further phenotypic analysis via flow cytometry may be conducted at day 7 for select samples of interest.
- the panel of cell surface markers under investigation includes CD4, CD8, CD27, CD28, CD3, CD57, CD25, and CD62L.
- FIGS. 3A and 3B shows clear, comparable performance of DBTA relative to the CD3/CD28 Dynabeads benchmark with respect to both early (days 1 and 4) % CD25 expression as well as x-fold cell expansion after days 4 and 7.
- Control samples with unmodified antibodies, RCA alone, unmodified antibodies with unconjugated nucleic acid sequence (free oligo) and cells only show very low level of activation and expansion, as expected.
- the robustness of the DBTA system is also confirmed as the standard deviations of activation and expansion match those observed with Dynabeads.
- FIGS. 3A and 3B includes data from five separate experiments, seven individual human T cell donors, and 4 different batches of antibody conjugates.
- FIG. 4A and 4B show that significant activation and expansion (relative to control) can also be achieved with a DBTA system wherein only the anti-CD3 antibody is attached to the o20b(+)act (anti-CD3-o20b(+)act).
- FIG. 4A shows the CD25 expression of the cultures after 24 hrs while FIG. 4B shows the CD25 expression of the same cultures after 4 and 7 days of expansion. However, the best performance is achieved when both anti-CD3 and anti-CD28 antibodies are attached to DNA to form the Ab-DNA conjugates.
- the data for FIG. 4 represents averages taken from over 5 separate experiments encompassing over six individual human T cell donors.
- Example 5 Comparison of Large-Scale T Cell Activation and Expansion Using Dynabeads® (ThermoFisher Scientific, Waltham, Mass.) Human T-Expander CD3/CD28 and a DBTA System of Nucleic Acid Polymers (RCAact) with Ab-DNA Conjugates (Anti-CD3-o20b(+)Act and Anti-CD28-o20b(+)Act)
- Example 4 In addition to 6-well plate studies, a large scale comparison of T cell activation and expansion efficiency using 72C VueLife® bags (Cell Genix GmbH, Breisgau, Germany) was also undertaken. The same ratios and components described in Example 4 were scaled linearly to accommodate starting conditions of 32 ⁇ 10 6 cells in 32 mL of complete X-Vivo media (1 ⁇ 106 cells/ml). The cultures were maintained in the 72C VueLife bags within a standard cell culture incubator. On Day 4, cells were collected, washed with fresh media, counted, diluted in appropriate media volume to give 0.5 ⁇ 106 cells/mL and re-seeded within the VueLife 72C.
- FIGS. 5A and 5B shows that comparable levels of both early activation (24-hour % CD25 expression) and day 4 cell expansion is achieved whether or not the all the DBTA components are pre-incubated/pre-associated (anti-CD3-DNA/anti-CD28-DNA DBTA pre-associated) together or added simultaneously at the start of cell activation (anti-CD3-DNA/anti-CD28-DNA DBTA in-situ)
- FIG. 5A is after 24 hr incubation and 5 B is after 4 days. Both sets of DBTA samples likewise compare favorably to benchmark Dynabead numbers for activation and early expansion. This data is derived from two separate experiments featuring four different human T cell donors and four different batches of Ab-DNA conjugates.
- FIG. 6A shows that sufficient T cell activation (24-hour % CD25 expression) and FIG. 6B cell expansion (days 4 and 7) are achieved at a variety of input quantities of antibody and RCAact product.
- the lowest input quantities of both antibody conjugate (0.25 ⁇ g/mL input or ⁇ 170 pM) and the corresponding RCAact product ( ⁇ 17 nM) showed the lowest levels of 24-hour % CD25 expression (60%), although this level of activation still far exceeds the cells-only negative control (20%) and eventually leads to day 7-fold expansion that matches the benchmark Dynabead samples.
- FIG. 7A highlights a greater than two-fold lower early activation (24-hour % CD25 expression) and FIG. 7B shows diminished day 7 cell expansion for the Ab-DNA/cell pre-incubated sample (anti-CD3-DNA/anti-CD28-DNA DBTA (Ab-DNA/cells pre-incubated)) relative to both standard DBTA samples (featuring simultaneous addition of all components) (anti-CD3-DNA/anti-CD28-DNA DBTA in situ) and Dynabead controls.
- FIG. 7B also shows results of expansion after 4 days.
- FIGS. 8A and 8B shows that optimal T cell activation (% CD25 expression) is achieved for both CpG and no CpG RCA at the anti-CD3-DNA:RCAact ratio of 1:10. Diminished activation efficiency is observed at both higher and lower ratios of Ab-DNA-to-RCA. All samples, however, demonstrate day 7 T cell expansion of about 10-fold or greater, matching or exceeding the Dynabead control sample.
- FIG. 8A is after 1 and 4 day culture showing % CD25
- FIG. 8B is after 4 and 7 days showing x-fold expansion.
- Example 10 Demonstration of Human T Cell Activation and Expansion Using an Alternative DBTA System with a Different Sequence and Oligo Length
- Sequence (5′ ⁇ length 3′) including SEQ ID Name sense (b) modifications NO use/application RCA primer - 20 ATC AAT GAT 5 primer for RCA reactions, sequence derived (MRSA) GCA TAA CAT CT from MRSA genome RCA template + 43 /Phos/CAT CAT 6 template for RCA reactions, sequence derived (MRSA) TGA TTT AGA from MRSA genome CAC TGA AAA AGT TCG AGG AGA TGT TAT G o25b(+)mrsa + 25 /MalC6/CAT CAT 7 conjugation to Ab via 5'-maleimide and binding TGA TTT AGA to MRSA-derived RCA product CAC TGA AAA A
- FIGS. 9 A and 9 B shows clear, comparable performance of DBTA component (anti-CD3-DNA conjugate only with soluble anti-CD28 Ab) relative to the CD3/CD28 Dynabeads benchmark with respect to both early (days 1 and 4) % CD25 expression ( FIG. 9A ) as well as x-fold cell expansion after days 4 and 7 ( FIG. 9B ).
- DBTA component anti-CD3-DNA conjugate only with soluble anti-CD28 Ab
- Example 11 Demonstration of Human T Cell Activation and Expansion Using a DBTA System Featuring Cleaved RCA Polymeric Products
- FIGS. 10A and 10B shows that the larger the RCA product, the higher the activation ( FIG. 10A % CD25 expression) and fold-expansion for the early days 1-4 of the experiment, while the trend becomes less pronounced later in the study. In particular, by day 7, all the three RCA products of different sizes yield comparable levels of cell expansion ( FIG. 10B ).
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
- The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Sep. 26, 2016, is named 312704-1_SL.txt and is 2,065 bytes in size.
- Cellular therapies, T cell therapies in particular, have shown remarkable success in treating hematological tumors and show promise in the treatment of solid tumors. These treatments require isolation of a patient's PBMC's or T cells and subsequent expansion (activation and proliferation) to generate a personalized therapeutic dose.
- For the most part this type of personalized therapy consists of removing blood cells from cancer patients; isolating and activating T cells; genetically modifying the T cells thereby programming those cells to recognize and attack cancer cells; expanding the T cells; and, lastly, introducing those cells back into the body so the patient's immune system can take over. Activation is a critical component of the whole process as it is required for efficient introduction of genetic material and for robust expansion.
- Several technology platforms exist in the commercial space, super paramagnetic, nonpyrogenic polystyrene beads with antibodies covalently bound to the surface, such as Dynabeads® CD3/CD28 CTS' (Life Technologies, Beverly, Mass.) is one of the most widely used to provide for isolation, activation and expansion of T cells. Still, in using bead based clustering and cell activation, significant cell loss is observed using the bead platform. This is related to bead removal after cell expansion is complete. Alternate technologies, such as the activator from StemCell Technologies that circumvent the issue of bead removal, are not very effective for cell activation, particularly early in the activation phase when the viral transduction is generally carried out.
- As such a new technology platform is desired that will provide novel approaches to cluster the T-cell surface receptors required for T cell activation and provide co-stimulatory signals to increase proliferation.
- Disclosed herein are methods for activating T cells, the method comprising providing a population of T cells, adding a plurality of first agents, wherein the first agent comprises a T-cell activator and a first binder moiety; adding a second agent comprising a plurality of capture oligomers, wherein at least a segment of at least one of the plurality of capture oligomers is capable of associating with the first binder moiety; and incubating the population of T cells after steps (b) and (c), whereby at least a portion of the population of T cells is activated. The method may further comprise the addition of a T-cell co-stimulator.
- In some embodiments, the present invention is a method for activating T cells, the method comprising providing a population of T cells, adding a plurality of first agents, wherein the first agent comprises a T-cell activator attached to a nucleic acid sequence; adding a nucleic acid polymer comprising a plurality of capture oligonucleotides, wherein at least a segment of at least one of the plurality of capture oligonucleotides is capable of associating with the nucleic acid sequence; and incubating the population of T cells after steps (b) and (c), whereby at least a portion of the population of T cells is activated. The method may further comprise the addition of a T-cell co-stimulator. In some embodiments the T-cell co-stimulator is attached to a nucleic acid sequence, wherein at least a segment of at least one of the plurality of capture oligonucleotides is capable of associating with the nucleic acid sequence attached to the T-cell co-stimulator.
- In some embodiments the present invention relates to a kit comprising a T cell activator attached to a nucleic acid sequence; and a nucleic acid polymer comprising a plurality of capture oligonucleotide sequences, wherein the nucleic acid sequence is complementary to at least a segment of at least one of the capture oligonucleotide sequences.
-
FIG. 1A-1E are representative flow cytometry histograms for positively validated anti-CD3-o20b(+)act and anti-CD28-o20b(+)act conjugates binding to T cells. 1A: Binding of a DNA (o20b(+)act) attached anti-CD28 antibody to T cells, 1B: Binding of corresponding unconjugated anti-CD28 antibody (positive control), 1C: Binding of a DNA (o20b(+)act) attached anti-CD3 antibody to T cells, 1D: Binding of corresponding unconjugated anti-CD3 antibody (positive control), and 1E, Cell incubated with labeled secondary antibody (negative control). -
FIG. 2 is an illustration of the preparation of single stranded rolling circle amplification (ssRCA) to produce RCA products (RCAact) for T cell activation in two steps. -
FIG. 3A is graphical representation of T cell activation measured as population of cells expressing CD25 receptor (a marker of T cell activation) by DBTA (DNA-Based T cell Activation) relative to the CD3/CD28 Dynabeads benchmark with respect to both early (days 1 and 4) % CD25 expression. Also shown are various controls including unconjugated antibodies alone and cells alone (without activator) not expected to cause significant activation. -
FIG. 3B is a graphical representation of the same cultures as inFIG. 3A atdays -
FIG. 4A is a graphical representation showing significant activation (relative to control) achieved with different DBTA systems, a DBTA system wherein only the anti-CD3 antibody is attached to the o20b(+)act (anti-CD3-o20b(+)act) and another DBTA system wherein both anti-CD3 and anti-CD28 are attached to o20b(+)act. Measured is the % CD25 expression. -
FIG. 4B is a graphical representation of the same cultures asFIG. 4A after 4 and 7 days showing x-fold expansion (cell counts) as inFIG. 3B . -
FIG. 5A is a graphical representation showing a trend towards higher activation when the DBTA components are mixed in situ compared to when they are pre-incubated/pre-associated and then mixed with cells. -
FIG. 5B is the same cultures asFIG. 5A after 4 days showing x-fold expansion (cell counts). -
FIG. 6A is a graphical representation showing T cell activation (24-hour % CD25) under a variety of conditions including different ratios of anti-CD3-DNA and anti-CD28-DNA with same RCA amount (10 RCA repeat units/per anti-CD3-DNA conjugate) and different amounts of DBTA reagent while keeping the ratio of anti-CD3-DNA conjugate and RCA repeat unit constant at 1:10. -
FIG. 6B is a graphical representation of cell expression of the same cultures asFIG. 6A afterdays -
FIG. 7A is a graphical representation of greater than two-fold lower early activation (24-hour % CD25 expression) for sample where cells were pre-mixed with anti-CD3 and anti-CD28 DNA conjugates for 30 minutes prior to adding RCA compared to all three DTBA components added at once (one after another). -
FIG. 7B is a graphical representation of the same cultures asFIG. 7A showing diminishedday 7 cell expansion (x-fold expansion, cell counts). -
FIG. 8A is a graphical representation showing T cell activation (% CD25 expression) is achieved for both CpG and no CpG RCA at different ratios (1:1, 1:10 and 1:100) of the anti-CD3-DNA:RCAact. -
FIG. 8B is a graphical representation of the same cultures asFIG. 8A showing x-fold expansion (cell counts) after 4 and 7 days. -
FIG. 9A is a graphical representation showing T cell activation with a different DNA sequence (a portion of MRSA (Methicillin-resistant Staphylococcus aureus) sequence) attached to the anti-CD3 antibody and its complementary RCA product. -
FIG. 9A is a graphical representation of the same cultures inFIG. 9A showing x-fold cell expansion afterdays -
FIG. 10A is a graphical representation showing that the larger the RCA product, the higher the activation (% CD25 expression). -
FIG. 10B is a graphical representation of the same cultures inFIG. 10A showing higher x-fold expansion (cell counts) with larger product in early expansion phase (day 4), however, byday 7 all the three RCA products of different sizes yield comparable levels of cell expansion. - The singular forms “a” “an” and “the” include plural referents unless the context clearly dictates otherwise. Approximating language, as used herein throughout the specification and claims, may be applied to modify any quantitative representation that could permissibly vary without resulting in a change in the basic function to which it is related. Accordingly, a value modified by a term such as “about” is not to be limited to the precise value specified. Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as molecular weight, reaction conditions, so forth used in the specification and claims are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the following specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the present invention. At the very least each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques.
- While certain embodiments are directed towards autologous cell therapies that involve collection, manipulation, and re-insertion of a patient's own cells, the applications of the disclosed techniques may include allogenic cells, modified human cells, or xenotransplantation of non-human cells. Cell based therapies that are contemplated as being used in conjunction with the disclosed techniques may include therapies for organ or tissue regeneration, cancer treatment, blood disorders, immunotherapies, heart disease, or any other cell-based therapies. A variety of cell types may be utilized within the context of the present invention including for example, but not limited to, cell types such as B cells, T-cells, or natural killer cells. The cells can be isolated from any tissue such as peripheral blood, bone marrow, or tumor tissue. Some embodiments are directed towards T cells enriched from peripheral blood by centrifugation using for example Ficoll-Paque™ or Percoll™ (GE Healthcare) gradient. Some other embodiments are directed towards a specific subpopulation of T-cells, such as CD28+, CD4+, CD8+, CD45RA+, and/or CD45RO+ T cells, further isolated by positive or negative selection techniques.
- As used herein “second agent” refers to a polymer comprising a plurality of capture oligomers, wherein at least a segment of at least one of the plurality of capture oligomers is capable of associating with a first binder moiety. In some embodiments the second agent is a nucleic acid polymer such as a rolling circle amplification product and the “capture oligomer” is a capture oligonucleotide sequence. The nucleic acid polymer may comprise a plurality of the same or different capture oligonucleotide sequences. In some embodiments the number of capture oligonucleotide sequences in the nucleic acid polymer is greater than 3, preferably greater than 30, and more preferably greater than 300. In certain embodiments, the number of capture oligonucleotide sequences is greater than 2000. As such, the nucleic acid polymer may comprise a plurality of capture oligonucleotide sequences of the same or different nucleotide sequence, molecular weights, geometrical arrangements, and/or patterns of repetition. In some embodiments, the capture oligonucleotide sequence may have a length in range of from about 6 nucleotides to about 12 nucleotides, from about 12 nucleotides to about 25 nucleotides, from about 25 nucleotides to about 50 nucleotides, from about 50 nucleotides to about 100 nucleotides, from about 100 nucleotides to about 250 nucleotides, or from about 250 nucleotides to about 500 nucleotides. In some agents the second agent is double-stranded nucleic acid polymer while in other embodiments it is a single-stranded nucleic acid polymer. The nucleic acid polymer may include natural or unnatural nucleotides with modifications on the nucleic acid base, sugar or phosphate backbone. The second agent may further comprise spacer oligonucleotide sequences having different number and/or sequence of nucleotides than the capture oligonucleotide sequences, or non-nucleic acid spacer molecules. In some other embodiments the second agent is a cationic polymer comprising a plurality of capture cationic oligomers, containing contiguous stretches of cationic monomers such as histidine or lysine. The second agent may further comprise neutral or anionic spacer residues provided the overall charge remains cationic. In still other embodiments the second agent is an anionic polymer comprising a plurality of capture anionic oligomers, containing contiguous stretches of anionic monomers such as acrylate. The second agent may further comprise neutral or cationic spacer residues provided the overall charge is anionic.
- As used herein, the term “first agent” refers to a cell activator attached to a “first binder moiety”. In some embodiments, the cell activator is a T-cell activator. The term “first binder moiety” refers to a molecule that can associate with one or more capture oligomers. In some embodiments the first binder moiety is a nucleic acid sequence and the “second agent” is a nucleic acid polymer comprising a plurality of capture oligonucleotide sequences, such that the nucleic acid sequence of the first binder moiety is complementary to at least a segment of at least one of the plurality of capture oligonucleotide sequences. The nucleic acid sequence of the first binder moiety and the capture oligonucleotide sequence are capable of associating via complementary base-pair hybridization. The first binder moiety and the capture oligonucleotide may hybridize to form a double or triple helix structure depending on whether the nucleic acid polymer is a double-stranded nucleic acid polymer or a single-stranded nucleic acid polymer. In some embodiments, all the nucleotide residues of at least one capture oligonucleotide sequence may hybridize to complementary nucleotides in the first binder moiety. For example, at least one capture oligonucleotide sequence may have 50 nucleotide residues and all the 50 nucleotide residues may hybridize to complementary nucleotides in the first binder moiety. In some embodiments, all the nucleotides of the capture oligonucleotide sequence may not have corresponding complementary nucleotides in the nucleic acid sequence of the first binder moiety. In some embodiments, there may be one or more base-pair mismatches between the capture oligonucleotide sequence and the nucleic acid sequence of the first binder moiety. In still other embodiments the capture oligonucleotide sequence and/or the nucleic acid sequence of the first binder moiety may include nucleic acid analogs, with modified bases such as azidothymidine, inosine, or uridine, or modified sugars, e.g. 3′-OMe, or modified backbone, e.g. phosphorothioate, alkylphosphonate, phosphoramidate backbones. The first or second agent may further comprise non-complementary spacer oligonucleotide sequences or non-nucleic acid spacer molecules. In some other embodiments the first binder moiety is an anionic moiety such as a nucleic acid sequence, alginate, polyglutamate, polyaspartate or hyaluronate and the second agent is a polymer comprising a plurality of cationic capture oligomers. The anionic first binder moiety is capable of associating with at least a segment of at least one of the plurality of cationic capture oligomers via electrostatic association. In still other embodiments, the first binder moiety is a cationic moiety and the second agent is a polymer comprising a plurality of anionic capture oligomers.
- As used herein, the term “T-cell activator” refers any agent that can activate a T-cell for proliferation and/or transduction. Suitable examples of T-cell activator include small organic molecules (for example ionomycin, phorbol myristate or acetate), natural or modified peptides, proteins (for example antibodies or affibodies), non-natural peptide mimics, nucleic acids (for example polynucleotides, PNA, DNA, RNA or aptamers), polysaccharides (for example lectins or sugars), lipids, enzymes, enzyme substrates or inhibitors, ligands, receptors, antigens, or haptens. In some embodiments, the T-cell activator binds to a T-cell surface receptor, such as a T-cell activating receptor, which results in delivery of a primary activation signal in a T-cell. T-cell activating receptors include for example T-Cell Receptor (TCR) or CD3 receptor. A primary activation signal can be initiated through binding between a TCR and an antigen presented in conjunction with either MHC class I or class II molecules, in order to stimulate an antigen-specific T-cell activation. A primary activation signal can also be initiated through binding between a CD3 receptor and a ligand targeted to the CD3 receptor, in order to stimulate a polyclonal T-cell activation. In exemplary embodiments the T-cell activator is an anti-CD3 antibody or fragments thereof. Other examples of T-cell activator include concanavalin A, protein kinase C (PKC) activator such as a phorbol ester (for example phorbol myristate acetate) or calcium ionophore (for example ionomycin which raises cytoplasmic calcium concentrations) and others. In some embodiments a first agent that binds to a TCR or a CD3 receptor may be used in conjunction with other T-cell activators.
- In some embodiments, the method of activating T cells comprises the addition of a plurality of a 1st population of first agents, wherein all the first agents in the 1st population of first agents comprises T-cell activator of the same type, such as an anti-CD3 antibody. In some embodiments, the method may further comprise the addition of a 2nd, 3rd, . . . nth population of first agents. The T-cell activators among different populations of first agents may be of the same type or different types such as anti-CD3 antibodies or fragments thereof or antigens bound to MHC molecules.
- In some embodiments, the method of activating T cells further comprises the addition of a T-cell co-stimulator. Examples of T-cell co-stimulators include ligands targeted towards T-cell co-stimulatory receptors such as CD28, CD2, ICOS, OX40, or 4-IBB receptors. Suitable ligands may include one or more of natural or modified peptides, proteins (for example antibodies, affibodies), non-natural peptide mimics, nucleic acids (for example polynucleotides, PNA, DNA, RNA, or aptamers), polysaccharides (for example lectins, sugars), lipids, enzymes, enzyme substrates or inhibitors, ligands, receptors, antigens, or haptens. The addition of a T-cell co-stimulator may include the addition of one or more types of T-cell co-stimulators. In some embodiments the T-cell co-stimulator may be attached to a second binder moiety. The term “second binder moiety” refers to a molecule that can associate with one or more capture oligomers. In some embodiments, the second agent is a nucleic acid polymer and the second binder moiety is a nucleic acid sequence, which is same as or different from the nucleic acid sequence of the first binder moiety. In some other embodiments the second agent is a cationic polymer and the second binder moiety is an anionic moiety. In still other embodiments the second agent is an anionic polymer and the second binder moiety is a cationic moiety.
- The term “attached” refers to any means of attachment known in the art. A T-cell activator can be attached to a first binder moiety by any means provided the attachment does not interfere with the activator's ability to activate T cells. Similarly, a T-cell co-stimulator can be attached to a second binder moiety by any means provided the attachment does not interfere with the co-stimulator's ability to provide a co-stimulatory signal to the T cell. The attachment may be covalent or noncovalent, electrostatic, or hydrophobic. In a preferred embodiment the attachment is covalent.
- In a preferred embodiment the T-cell activator is an anti-CD3 antibody attached to a nucleic acid sequence, the T-cell co-stimulator is an anti-CD28 antibody attached to a nucleic acid sequence, and the second agent is a rolling circle amplification product comprising a plurality of complementary capture oligonucleotide sequences.
- In preferred embodiments the first agent and the second agent are soluble in cell culture media. As to be understood, “cell culture media” refers to any standard T cell culture media, which are known in the art. Illustrative media include but are not limited to RPMI 1640, AIM-V, DMEM, MEM, α-MEM, F-12,
X-Vivo 15. The T cell culture media may be serum-free or supplemented with serum, such as human serum or serum supplement. In some embodiments, the T cell culture media is further supplemented with additional growth factors and cytokines such as interleukin-2 (Il-2), interleukin-7 (Il-7) or interleukin-15 (IL-15). - As used herein, the term “in situ” generally refers to an event occurring in the original location, for example in the location where T cell activation occurs. In some embodiments “in situ” refers to an event happening in the T cell culture media under cell culturing condition.
- The invention includes embodiments that relate generally to methods of activating T cells for cellular therapy. In some embodiments, the method includes the addition of a plurality of first agents, each first agent comprising a T-cell activator attached to a first binder moiety, wherein the T-cell activators are capable of binding to a set of T-cell surface receptors, such as the T-cell activating receptors, inducing a cellular event within the T cells that leads to activation and proliferation of the cells. In some embodiments a clustering of the T-cell surface receptors is induced by a second agent, which associates with the first binder moiety bringing the T-cell activators in proximity to each other. In some embodiments, the method further includes the addition of a plurality of T-cell co-stimulators capable of binding to a different set of T-cell surface receptors, such as the T-cell co-stimulatory receptors. The T-cell co-stimulator may be attached to a second binder moiety. The second agent associates with both the first binder moiety and the second binder moiety thereby inducing a clustering of the T-cell surface receptors. In some embodiments the second agent is a nucleic acid polymer comprising a plurality of capture oligonucleotide sequences and the association is caused by base-pair hybridization between a nucleic acid sequence attached to the T-cell activator and a complementary capture oligonucleotide sequence. In some embodiments the method further comprises the addition of a T-cell co-stimulator attached to a second binder moiety, wherein the second binder moiety is also a nucleic acid sequence, and the nucleic acid sequence is capable of association with a complementary capture oligonucleotide sequence by base-pair hybridization. In some embodiments the association of the capture oligomer with the first binder moiety and the second binder moiety is caused by electrostatic interaction between oppositely charged species for example anionic moieties attached to the T-cell activator and T-cell co-stimulator with cationic capture oligomers or vice versa.
- In some embodiments, the first agent, the second agent, and optionally a T-cell co-stimulator, which may or may not be attached to a second binder moiety, are added simultaneously or sequentially in any order, to a population of T cells provided in a cell culture media, to allow an in-situ association. In still other embodiments, the first agent, the second agent, and optionally a T-cell co-stimulator attached to a second binder moiety, are allowed to pre-incubate and associate to form a pre-associated complex. The pre-associated complex is then added to the population of T cells. In preferred embodiments, the first agent, the second agent, and optionally the T-cell co-stimulator attached to a second binder moiety, are allowed to associate in-situ.
- The T cells are incubated with the first agent, the second agent, and optionally a T-cell co-stimulator for a period of time, whereby at least a portion of the population of T cells is activated. In some embodiments the T-cell co-stimulator is attached to a second binder moiety. In some embodiments the time sufficient to activate a portion of the population of T cells may range from about 1 minute to about 14 days. In certain embodiments, the time may be from about 24 h to about 8 days. In some embodiments, at least 15% of T cells are activated. In preferred embodiments at least 25% of the T cells are activated, and in more preferred embodiment the majority of the T cells, greater than 50% are activated. The incubation may be done in a bioreactor having a controlled environment of temperature, humidity, CO2 concentration, for example at 37° C. and 5% CO2. In some embodiments the incubation may be done in a static bioreactor where there is no movement of the bioreactor, while in some other embodiments the incubation may be done in a bioreactor placed on a rocking platform.
- In some embodiments the invention provides methods to activate and selectively expand a specific subpopulation of T cells from a mixed population of T cells. This can be achieved for example by varying the nature or relative proportion of the T-cell activators and T-cell co-stimulators. Further, the invention provides methods to control T-cell surface receptor clustering and hence activation by adjusting for example the number of or distance among the T-cell activators and T-cell co-stimulators, which are associated with the second agent. In an exemplary embodiment where the second agent is a nucleic acid polymer, this can be achieved by precisely controlling the number and/or length of the capture oligonucleotides, or the length of the spacers.
- The expression of certain antibodies such as CD25 may be used to measure the activation of the T cells. In certain embodiments the expression of CD25 receptors on the T cells may be assayed by labeled anti-CD25 antibodies to enumerate the labeled cells. In certain other embodiments, activation may be measured by other markers signifying T-cell surface receptor clustering, which induces activation and expansion. The other markers used to measure T cell activation and expansion include CD4, CD8, CD27, CD28, CD3, CD57, CD25, and CD62L.
- In preferred embodiments, the first agent and the second agents are bio-degradable. As used herein, the term bio-degradable refers to materials that degrade in biological fluid. In some embodiments, the degradation may occur using chemical or enzymatic means. In some embodiments, where the second agent is a nucleic acid polymer and/or the first binder moiety is a nucleic acid sequence, the method of activation of T cells further comprises the addition of a degrading enzyme such as a nuclease. In some embodiments the degrading enzyme, such as the nuclease, is added after at least a portion of the population of T cells is activated. In some embodiments, the degrading enzyme is added after the T cells have expanded at least 10-100 fold. In still other embodiments, the degrading enzyme is added at the end of the culture period, before the T cells are harvested from the cell culture media, prior to washing, concentration and final formulation. It should be noted that the degrading enzyme can be added any time after at least a portion of the population of T cells is activated and before the T cells are administered into a patient. In certain embodiments, after degradation, the degraded by-products of the first and second agents can be removed during washing and concentration of the T cells, and additional purification steps are not necessary. In some other embodiments, the second agent and the first agent are biocompatible and may be rapidly degraded in the blood stream. In such cases, the addition of a degrading enzyme may not be required before the T cells are administered into a patient. The use of such soluble, biodegradable systems are advantageous over polystyrene beads or other comparable bead based approaches since the use of such systems may avoid the need for additional purification steps, such as magnetic separation, which often leads to significant cell loss. In embodiments that include the addition of a T-cell co-stimulator attached to a second binder moiety, the second binder moiety is also biodegradable.
- In some embodiments, the method of T cell activation further comprises the addition of a vector comprising a foreign gene. In some embodiments the foreign gene encodes a chimeric antigen receptor or a T-cell receptor. In some embodiments, the vector is a viral vector such as a γ-retroviral vector or a lentiviral vector. In some other embodiments the vector is a plasmid vector. In some embodiments the vector is added simultaneously with the first agent, while in some other embodiments, the vector is added after at least a portion of the population of T cells is activated.
- Some embodiments are directed towards a kit comprising a T-cell activator attached to a nucleic acid sequence, a nucleic acid polymer comprising a plurality of capture oligonucleotide sequences, and optionally a T-cell co-stimulator. In some embodiments the T-cell co-stimulator is attached to a nucleic acid sequence, which is same as or different from the nucleic acid sequence attached to the T-cell activator. In specific examples the kit is a DNA-Based T cell Activation (DBTA) construct comprising a DNA polymer such as a rolling circle amplification product and one or more of the following components, i) a T-cell activator attached to a DNA sequence (first binder moiety), and ii) a T-cell co-stimulator attached to a DNA sequence (second binder moiety), which is same as or different from the DNA sequence attached to the T-cell activator.
- The following examples are intended only to illustrate methods and embodiments in accordance with the invention, and as such should not be construed as imposing limitations upon the claims.
- DNA-Based T cell Activation (DBTA) polymer constructs are representative nucleic acid polymer systems that initiate T cell clustering, activation, and subsequent expansion. DBTA comprises a DNA polymer produced via rolling circle amplification (such as RCAact) and consisting of repeating 43-base oligonucleotide segments and one or more of the following components: (1) anti-human CD3 monoclonal antibodies conjugated to 20-base DNA sequence derived from human beta-actin (o20b(+)act), (2) anti-human CD28 monoclonal antibodies also conjugated with DNA sequence o20b(+)act. The 43-base oligonucleotide segments bear full complementarity to the DNA sequences conjugated to the antibodies (1) and (2). The sequences of RCAact are derived from the complement to the RCA template sequences given below in Table 1:
-
TABLE 1 Modification key: Phos = 5′ phosphate, Mal = maleimide functional group, C6 = hexylamino modification Sequence (5′→ length 3′) including SEQ ID Name sense (b) modifications NO use/application RCA primer - 20 TGA CTA TTA 1 primer for RCA reactions, sequence derived AGA CTT CCT GT from human beta-actin RCA + 43 /Phos/ TTA ATA 2 template for RCA reactions, sequence template GTC ATT CCA derived from human beta-actin and (CpG) AAT ATG AGA contains CpG island TGC GTT GTT ACA GGA AGT C RCA + 43 /Phos/ TTA ATA 3 template for RCA reactions, sequence template GTC ATT CCA derived from human beta-actin and does (no CpG) ACA TAT GAG not contain CpG island ATG GTT GTT ACA GGA AGT C o20b(+)act + 20 /MalC6/ ACA 4 conjugation to Ab via 5′-maleimide and GGA AGT CTT binding to human B-actin-derived RCA AAT AGT CA product - The covalent attachment of DNA sequences to antibodies (Abs) proceeds via a maleimide-thiol coupling strategy as described below. The following specific description of anti-CD3-o20b(+)act and anti-CD28-o20b(+)act conjugate synthesis, purification, and characterization can be adapted as a general conjugation strategy for different antibody (Ab) clones as well as nucleic acid sequences of different length and composition.
- The starting nucleic acid sequence (prot-mal-o20b(+)act) is provided by TriLink Biotechnologies and comprises a 20-base DNA sequence capped with an N-terminal C6 spacer followed by a protected tricyclic maleimide moiety. Upon receipt of this commercial material, a reactive mal-o20b(+)act derivative is generated via an inverse electron-demand Diels-Alder deprotection step, whereby the starting nucleic acid sequence is suspended in anhydrous toluene (˜1 mg/mL) and heated at 90° C. for 4 h. Precipitation of the nucleic acid sequences via benchtop centrifugation and removal of solvent is followed by several washes (3×1 mL) with cold ethanol. Upon further reduction of residual organic solvents under reduced pressure, the washed solid product is dissolved in 100 mM HEPES buffer, pH 7.3 and the solution concentration is determined via UV-Vis spectroscopy (NanoDrop). The resulting stock solution (0.5-1 mM in DNA) or a portion thereof may be used directly for antibody conjugation with thiol-modified antibody. The remaining mal-o20b(+)act stock may be stored for several months at −20° C. without significant loss of reactivity.
- A 10 mM stock solution of Traut's reagent (2-aminothiolane hydrochloride) is first prepared in 100 mM HEPES buffer, pH 7.3. A 1 mg/mL solution of anti-CD3 Ab (OKT3 clone, eBioscience) or anti-CD28 Ab (9.3 clone, GeneTex) in PBS is then mixed with both 20× pH 8.5 borate buffer (ThermoFisher) and 10 mM Traut's reagent stock solution in a 8:1:1 ratio by volume. The resulting solution is thoroughly mixed and allowed to incubate at room temperature for 0.75 h. The unused portion of the Traut's mixture may be stored for several months at −20° C. without significant loss of reactivity. Following antibody activation, the reaction mixture is purified using a conventional desalting column (e.g. NAP-5 or PD-10, GE Healthcare Life Sciences) that has been equilibrated with 100 mM HEPES, pH 7.3 buffer. The collected fractions are then immediately analyzed by UV-Vis spectroscopy (NanoDrop). The resulting protein recovery at this stage is typically >60% for both anti-CD3 and anti-CD28 antibodies using known molar extinction coefficients for antibody at 280 nm.
- Conjugation of Maleimide-Activated DNA Sequences with Thiol-Modified Ab Intermediates to Generate Ab-DNA Conjugates
- For the final Ab-DNA attachment step, the volume of mal-o20b(+)act corresponding to a target molar input ratio of 10-40:1 o20b(+)act:Ab is added to an aliquot of freshly prepared, purified, thiol-activated Ab. After thorough mixing, the resulting solution is allowed to incubate at room temperature overnight (16-24 h). Final conjugate purification is achieved via selective precipitation of Ab using a saturated ammonium chloride solution. First, a volume of saturated ammonium chloride equal to the total reaction volume is added, thoroughly mixed, and placed on ice. After 15 min, the sample is centrifuged at 15,000×g rcf for 10 min at 10° C. Removal of the supernatant is followed by addition of an appropriate minimum volume of 0.1M sodium phosphate, 0.15M NaCl,
pH 7 buffer to re-dissolve the final pellet. The final antibody-DNA conjugate recovery and labeling efficiency (attached Ab-DNA) is determined using the Pierce BCA Protein Assay Kit (Thermo Scientific) in combination with NanoDrop A260 measurement for determination of DNA content (ε=210,100 M−1 cm−1). Under these condition an average of 1-3 o20b(+)act oligonucleotide molecules are conjugated to each molecule of anti-CD3 or anti-Cd28 antibody. Attachment is generally achieved with a final conjugate recovery of >60%. Further confirmation of conjugate purity is determined using analytical size exclusion chromatography (SEC) against a standard protein size calibration curve. Typical analytical SEC conditions are as follows: 10 μL sample injection volume, 0.5 mL/min flow rate, 30 min run using 100 mM sodium phosphate, 100 mM sodium sulfate, 0.05% sodium azide, pH 6.7 buffer on a TSK Gel 3000SW×L column (TOSOH Bioscience). Typical analytical SEC elution times are as follows: unlabeled Ab=16.8-17.0 min, starting o20b(+)act=20.0 min, Ab-DNA (Ab-o20b(+)act) conjugate mixture=10-15 min. Purified final Ab-DNA conjugates (after precipitation and resuspension) show >95% removal of unbound DNA intermediate or starting material upon SEC analysis. - To ensure that the Ab-DNA conjugates prepared in Example 1 retain their specific cell binding capabilities to T cells, validation studies are performed for each conjugate batch using flow cytometry (Cytoflex S, Beckman Coulter). NBP Pan T Cells (ALL Cells) are thawed at 37° C. in 10 mL warm complete media (see Example 4) and then centrifuged at 300×g rcf for 10 min. Cells are then resuspended in 10 mL fresh complete media and analyzed on a Nucleocounter® NC-200 system to determine cell counts and viability. After adjusting the concentration to 1×106 cells/mL and washing with PBS, the T cells are then blocked in 10% Normal Goat Serum (NGS) in PBS at 4° C. for 15 min. After removal of the blocking solution, cells are then incubated with primary antibody in 1% NGS/PBS solutions for 15 min at 4° C. In parallel, both anti-CD3-DNA and/or anti-CD28-DNA conjugate (anti-CD3-o20b(+)act and/or anti-CD28-o20b(+)act) test samples (Example 1) as well as unlabeled or unconjugated anti-CD3 and/or anti-CD28 Ab positive controls (Ab not attached to DNA) are used. After primary Ab incubation, cells are washed in PBS and incubated with a 1% NGS/PBS solution of fluorophore-labeled secondary antibody (Jackson Immuno) specific for the mouse isotype of both anti-CD3 and anti-CD28 Abs. Typical dilutions for secondary antibody labeling are 1:200 of a 1 mg/mL stock solution. After 15 min incubation at 4° C., cells are washed as before, resuspended in PBS and analyzed by flow cytometry to determine the percentage of T cells bound with Ab-DNA conjugate relative to the percentage of cells bound with unlabeled Ab (positive control).
- Representative flow cytometry histograms for positively validated anti-CD3-o20b(+)act and anti-CD28-o20b(+)act conjugates binding to T cells are shown in
FIG. 1A through 1E ; Anti-CD28-o20b(+)act, anti-CD28 unlabeled, Anti-CD3o20b(+)act, anti-CD3 unlabeled, and FITC-labeled respectively. For these particular Ab-DNA conjugate batches, high percentage of anti-CD3+ and anti-CD28+ cell binding is observed (>85% for both). These results indicate that despite DNA attachment, a significant portion of the anti-CD3 and anti-CD28 Ab samples retain their T cell binding capabilities. - Preparation of single stranded rolling circle amplification (ssRCA) to produce RCA products (RCAact) for T cell activation comprises two steps: 1) ligation of a linear DNA strand to generate a circular template, and 2) amplification of the ligated circle to synthesize long single stranded concatemers. The ligation was accomplished using a high concentration of T4 DNA Ligase and its corresponding reaction buffer (New England Biolabs®) Two deoxyoligonucleotides (oligonucleotide) were present in the ligation. One oligonucleotide (RCAact-NoCG) consisted of 43 bases of the DNA sequence of the human β-actin gene and contained a 5′ phosphate group. This 43 base oligonucleotide would become the circular template following ligation. The second oligonucleotide was 20 bases in length (RCAact Primer) and was complimentary to both ends of the 43 base oligonucleotide. This second oligonucleotide was used to both form the circle prior to ligation and then amplify the circle in the subsequent ssRCA reaction (see
FIG. 2 ). 450 pmol of the 43 base oligonucleotide were mixed in a 120 μL volume with 300 pmol of the 20 base oligonucleotide in an annealing buffer consisting of 10 mM Tris,pH - The ssRCA reaction was prepared by mixing 69.3 μL of the completed ligation reaction with 550 μL of 2× Phi29 Reaction Buffer (100 mM HEPES Buffer, pH 8.0, 150 mM potassium chloride, 2 mM TCEP, 40 mM magnesium chloride, 0.02% (v/v)
Tween - The apparent size of RCAact products is determined by pulse field gel electrophoresis relative to yeast (S. cerevisiae) or lambda DNA molecular weight ladders. In addition to pulse-field analysis, gel-shift assays using non-denaturing agarose gels are used to confirm hybridization of anti-CD3-o20b(+)act and anti-CD28-o20b(+)act conjugates (Example 1) with RCAact.
- Frozen aliquots of human Pan T Cells from AllCells (Catalog# PB009-IF) are used for all activation and expansion studies. Pan T Cells are thawed and processed as described in Example 2 and added to following complete X-Vivo media to give an initial concentration of 1×106 cells/mL as shown in Table 2.
-
TABLE 2 X-Viro media aliquots Final concen- tration Volume Component Vendor Cat# in media (ml) Human serum off Valley HS1017 5% 50 the clot Biomedical Glutamax 1-CTS Gibco A12860-01 1% 10 Pen-Strep ThermoFisher 15140-122 1% 10 N-acetyl cysteine Sigma A9165 0.8% 8 IL-2 Thermo Fisher 200-02 200 IU 0.152 X-Vivo media Lonza BE04-743Q 92% 1000 - Typical activation and expansion experiments are performed in a 6-well format using a 2 mL seeding volume per well with a minimum of one additional replicate per condition tested. Dynabeads® Human T-Expander CD3/CD28 (Catalog#111.41D, ThermoFisher) are prepared according to the manufacturer's instructions. Briefly, a bead aliquot is washed with 0.3 mL complete media three times, with supernatant wash removal occurring after sample application to DynaMag-2 permanent magnet (ThermoFisher). After resuspension in complete media, a 60 bead slurry aliquot is added per well such that an approximate 3:1 bead-to-cell ratio is used for initial activation conditions (starting with 2×106 total cells per well).
- Unless otherwise specified, aliquots of DBTA components (Ab-DNA and RCAact) are added separately and consecutively to cells directly from their respective stock solutions (stored at 4° C.). Additions of each DBTA component may be made in any sequential order. Standard initial concentrations of DBTA components are as follows: 1 μg/mL (6.7 nM) each for anti-CD3-o20b(+)act (anti-CD3-DNA) and anti-CD28-o20b(+)act (anti-CD28-DNA) with 10-fold molar excess of RCAact (˜67 nM). RCAact concentration is based on the molar concentration of the repeating 43-base segment and independent of total RCA product length or polydispersity. Following the addition of all of the appropriate activating components, the well contents are mixed with a 1 mL pipette. The plates are then incubated at 37° C. and 5% CO2 atmosphere under static conditions for 1-7 days or longer with periodic aliquots taken and, dilutions done with fresh media as needed for continuing expansion and analysis. Confirmation of cell activation is achieved by % CD25 expression using flow cytometry after 24 h incubation (day 1) and followed by additional measurements, if needed, at
days days day 4 cell counts, a 1:4 or 1:8 dilutions with fresh complete media is performed to reduce cell density to 250,000 cells/mL per well. This enables cells to expand in the exponential phase, without overgrowth, untilday 7 analysis. For the negative control (“cells-only”) sample group in which no activating agents are added, cell density is maintained at a minimum of 500,000 cells/mL. Further phenotypic analysis via flow cytometry may be conducted atday 7 for select samples of interest. The panel of cell surface markers under investigation includes CD4, CD8, CD27, CD28, CD3, CD57, CD25, and CD62L.FIGS. 3A and 3B shows clear, comparable performance of DBTA relative to the CD3/CD28 Dynabeads benchmark with respect to both early (days 1 and 4) % CD25 expression as well as x-fold cell expansion afterdays FIGS. 3A and 3B includes data from five separate experiments, seven individual human T cell donors, and 4 different batches of antibody conjugates.FIGS. 4A and 4B show that significant activation and expansion (relative to control) can also be achieved with a DBTA system wherein only the anti-CD3 antibody is attached to the o20b(+)act (anti-CD3-o20b(+)act).FIG. 4A shows the CD25 expression of the cultures after 24 hrs whileFIG. 4B shows the CD25 expression of the same cultures after 4 and 7 days of expansion. However, the best performance is achieved when both anti-CD3 and anti-CD28 antibodies are attached to DNA to form the Ab-DNA conjugates. The data forFIG. 4 represents averages taken from over 5 separate experiments encompassing over six individual human T cell donors. - In addition to 6-well plate studies, a large scale comparison of T cell activation and expansion efficiency using 72C VueLife® bags (Cell Genix GmbH, Breisgau, Germany) was also undertaken. The same ratios and components described in Example 4 were scaled linearly to accommodate starting conditions of 32×106 cells in 32 mL of complete X-Vivo media (1×106 cells/ml). The cultures were maintained in the 72C VueLife bags within a standard cell culture incubator. On
Day 4, cells were collected, washed with fresh media, counted, diluted in appropriate media volume to give 0.5×106 cells/mL and re-seeded within the VueLife 72C. OnDay 6, cells were diluted and seeded in 250 mL in the Wave bag, on a rocking WAVE platform for further expansion. ByDay 8, cells were counted using Nucleocounter® (ChemoMetec, Allerod, Denmark) and examined by flow cytometry for various CD surface marker expression. The tables below depict comparable levels of CD25 expression, x-fold expansion, cell size, and viability for both Dynabead samples and those activated with DBTA. In addition, theday 8 flow analysis shows nearly identical levels of phenotypic expression for the full panel of CD markers for both Dynabeads and DBTA. The preparation and results are illustrated in Tables 3-5 below. -
TABLE 3 Cell Counts at 4 and 8 days. Cell counts Fold X % CD25 Day 4 Day 4 ( total Day 8 Day 8/Sample (24 h) (cells/ml) viable cells) (cells/ml) Day 4Day 6DBTA >90% 8.45E+05 4.23E+07 1.57E+06 1.32 6.04 Dynabeads >90% 1.25E+06 6.25E+07 1.38E+06 1.95 5.31 -
TABLE 4 Cell Viability as a percentage of population. Day 8total Viable Cell size (μm) % Viability Sample Cells Day 4 Day 8Day 4Day 8DBTA 3.93E+08 12.2 10.9 98.1 97.5 Dynabeads 3.45E+08 12.1 11.0 97.6 97.1 -
TABLE 5 Cell Flow Cytometry results at 8 days. Flow Cytometry Results at day 8 (% cells positive): CD Marker DBTA Dynabeads CD8 46% 45% CD4 51% 53% CD3 96% 98 % CD25 80% 84 % CD57 10% 8% CD62L 95% 96% CCR7 62% 47% CD28 96% 95% CD27 98% 96% CD27+CD28+ 90% 82% - A series of T cell activation experiments were conducted to assess the effect of pre-incubating all of the DBTA system components (Anti-CD3-DNA and anti-CD28-DNA conjugates along with their complementary RCAact polymeric product) and then adding the pre-associated complex to T cells. The results were compared to the standard protocol of simultaneous addition of each separate component to T cells for in-situ association. For these pre-incubated samples, the same quantities and ratios of DBTA components used in Example 4 were added together in a 1.5 mL tube, mixed thoroughly, and incubated at room temperature for 30 minutes. The pre-incubated DBTA mixture was then added to fresh T cell cultures in the 6 well plates. In parallel, and as conducted in Example 4, standard DBTA samples not subjected to pre-incubation were added to T cell cultures along with standard Dynabead and cells only samples (positive and negative controls, respectively).
-
FIGS. 5A and 5B shows that comparable levels of both early activation (24-hour % CD25 expression) andday 4 cell expansion is achieved whether or not the all the DBTA components are pre-incubated/pre-associated (anti-CD3-DNA/anti-CD28-DNA DBTA pre-associated) together or added simultaneously at the start of cell activation (anti-CD3-DNA/anti-CD28-DNA DBTA in-situ)FIG. 5A is after 24 hr incubation and 5B is after 4 days. Both sets of DBTA samples likewise compare favorably to benchmark Dynabead numbers for activation and early expansion. This data is derived from two separate experiments featuring four different human T cell donors and four different batches of Ab-DNA conjugates. - A series of T cell activation experiments were conducted to assess the effect of different ratios of Ab-DNA conjugate and RCAact on T cell activation efficiency. In all cases, the same anti-CD3-DNA: RCAact molar ratio of 1:10 was maintained, while 1:1 versus 1:2 molar ratios of anti-CD3-DNA: anti-CD28-DNA conjugate were examined. All other protocol conditions outlined in Example 4 were maintained.
-
FIG. 6A shows that sufficient T cell activation (24-hour % CD25 expression) andFIG. 6B cell expansion (days 4 and 7) are achieved at a variety of input quantities of antibody and RCAact product. Not surprisingly, the lowest input quantities of both antibody conjugate (0.25 μg/mL input or ˜170 pM) and the corresponding RCAact product (˜17 nM) showed the lowest levels of 24-hour % CD25 expression (60%), although this level of activation still far exceeds the cells-only negative control (20%) and eventually leads to day 7-fold expansion that matches the benchmark Dynabead samples. It is noted that half the standard input quantity of Ab-DNA conjugate (0.5 μg/mL) and RCAact (33.5 nM) nonetheless achieves the same level of early activation (90%) as the Dynabead benchmark. The data for this example is derived from three separate experiments featuring five different human T cell donors and four different batches of Ab-DNA conjugates. - An experiment was conducted to assess the effect of adding the anti-CD3-DNA and anti-CD28-DNA antibody conjugates to T cell culture to generate a Ab-DNA/cell pre-incubated sample prior to a separate, second addition of RCA
polymeric product 30 min later. For this experiment, all other protocol details and quantities outlined in Example 4 were followed. -
FIG. 7A highlights a greater than two-fold lower early activation (24-hour % CD25 expression) andFIG. 7B showsdiminished day 7 cell expansion for the Ab-DNA/cell pre-incubated sample (anti-CD3-DNA/anti-CD28-DNA DBTA (Ab-DNA/cells pre-incubated)) relative to both standard DBTA samples (featuring simultaneous addition of all components) (anti-CD3-DNA/anti-CD28-DNA DBTA in situ) and Dynabead controls.FIG. 7B also shows results of expansion after 4 days. - A series of T cell activation experiments were conducted to assess the effect of different Ab-DNA conjugate-to-RCAact input ratios on T cell activation efficiency. In all cases, only anti-CD3-DNA (anti-CD3-o20b(+)act) conjugates were used. Each Ab conjugate sample, furthermore, featured the same standard concentration per well for activation (1 μg/mL input or ˜6.7 μM), while a three log range of input RCAact product was investigated (6.7 nM, 67 nM, and 670 nM) to give starting Ab-DNA:RCA ratios of 1:1, 1:10, and 1:100, respectively. In addition, both CpG and non-CpG RCA template variants (see Example 1) were investigated. For these experiments, all other protocol details and quantities outlined in Example 4 were maintained.
-
FIGS. 8A and 8B shows that optimal T cell activation (% CD25 expression) is achieved for both CpG and no CpG RCA at the anti-CD3-DNA:RCAact ratio of 1:10. Diminished activation efficiency is observed at both higher and lower ratios of Ab-DNA-to-RCA. All samples, however, demonstrate day 7 T cell expansion of about 10-fold or greater, matching or exceeding the Dynabead control sample.FIG. 8A is after 1 and 4 day culture showing % CD25,FIG. 8B is after 4 and 7 days showing x-fold expansion. - All previous examples (1-9) and associated FIGS. (1-8) for this disclosure successfully utilize a DBTA system featuring DNA sequences derived from human B-actin (Example 1). Successful human T cell activation and expansion may also be achieved with any number of alternative systems featuring different DNA sequences, base content, and oligo lengths. One alternative example features oligo and RCA products originally derived from the methicillin-resistant Staphylococcus aureus (MRSA) genome. The specific sequence information for each of these DBTA components is shown in Table 6 below:
-
TABLE 6 Sequence Information. Sequence (5′→ length 3′) including SEQ ID Name sense (b) modifications NO use/application RCA primer - 20 ATC AAT GAT 5 primer for RCA reactions, sequence derived (MRSA) GCA TAA CAT CT from MRSA genome RCA template + 43 /Phos/ CAT CAT 6 template for RCA reactions, sequence derived (MRSA) TGA TTT AGA from MRSA genome CAC TGA AAA AGT TCG AGG AGA TGT TAT G o25b(+)mrsa + 25 /MalC6/ CAT CAT 7 conjugation to Ab via 5'-maleimide and binding TGA TTT AGA to MRSA-derived RCA product CAC TGA AAA A -
FIGS. 9 A and 9B shows clear, comparable performance of DBTA component (anti-CD3-DNA conjugate only with soluble anti-CD28 Ab) relative to the CD3/CD28 Dynabeads benchmark with respect to both early (days 1 and 4) % CD25 expression (FIG. 9A ) as well as x-fold cell expansion afterdays 4 and 7 (FIG. 9B ). These results are comparable to the β-actin derived DBTA system shown in the above examples. Also as with the β-actin DBTA, the specificity of the system is confirmed: control samples with unmodified antibodies, RCA product alone, and cells only show very low level of activation and expansion. It is noted that the exact same Ab conjugation, RCA production, and cell culturing protocols and molar quantities described above for β-actin DBTA were also utilized for the MRSA system. - A comparison of human T cell activation and expansion efficiency using different sized RCA products was conducted using the MRSA-based DBTA system (See Example 10 and Example 3 for general conditions used to generate full length RCA product). For these experiments, full length RCA products were subjected to sonication conditions yielding different relative size distributions. To produce sonicated RCA products, a Covaris M220 Focused Ultrasonicator™ (Covaris, Woburn, Mass.) was utilized according to the manufacturer's recommended input conditions to yield 1500 bp and 150 bp sized fragments starting from large genomic DNA fragments. Target input parameters include peak incident power, duty factor, cycles per burst, treatment time, and temperature. After sonication, analytical size exclusion chromatography was used according to Example 1 conditions to confirm the relative size distributions of products. While absolute size and molecular weight determinations are unknown for the RCA products by this method, we observed the expected general trend of increasing elution time for smaller fragments. The following elution times were thus observed: 10.1 min (corresponding to the void volume) for ˜16 kb (theoretical maximum length) full length RCA product, 10.8 min for the 1.5 kb sonicated RCA product, 14.8 min for the 0.15 kb sonicated RCA product, 19.2 min for the starting 43b RCA template (control injection), 20.0 min for the unconjugated o25b(+)mrsa (control injection), and 23.7 min for residual small molecules including nucleotides.
-
FIGS. 10A and 10B shows that the larger the RCA product, the higher the activation (FIG. 10A % CD25 expression) and fold-expansion for the early days 1-4 of the experiment, while the trend becomes less pronounced later in the study. In particular, byday 7, all the three RCA products of different sizes yield comparable levels of cell expansion (FIG. 10B ). - While only certain features of the invention have been illustrated and described herein, many modifications and changes will occur to those skilled in the art. It is, therefore, to be understood that the appended embodiments are intended to cover all such modifications and changes as fall within the scope of the invention.
Claims (25)
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/245,584 US10294454B2 (en) | 2016-08-24 | 2016-08-24 | Methods and kits for cell activation |
US16/339,077 US11512288B2 (en) | 2016-08-24 | 2017-08-24 | Methods and kits for cell activation |
EP17769141.7A EP3504323A1 (en) | 2016-08-24 | 2017-08-24 | Methods and kits for cell activation |
PCT/US2017/048306 WO2018039400A1 (en) | 2016-08-24 | 2017-08-24 | Methods and kits for cell activation |
CN201780051673.1A CN109563484A (en) | 2016-08-24 | 2017-08-24 | Method and kit for cell activation |
JP2019510693A JP7043114B2 (en) | 2016-08-24 | 2017-08-24 | Methods and kits for activating cells |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/245,584 US10294454B2 (en) | 2016-08-24 | 2016-08-24 | Methods and kits for cell activation |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/339,077 Continuation US11512288B2 (en) | 2016-08-24 | 2017-08-24 | Methods and kits for cell activation |
Publications (2)
Publication Number | Publication Date |
---|---|
US20180057791A1 true US20180057791A1 (en) | 2018-03-01 |
US10294454B2 US10294454B2 (en) | 2019-05-21 |
Family
ID=59914514
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/245,584 Active 2036-09-10 US10294454B2 (en) | 2016-08-24 | 2016-08-24 | Methods and kits for cell activation |
US16/339,077 Active 2038-12-07 US11512288B2 (en) | 2016-08-24 | 2017-08-24 | Methods and kits for cell activation |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/339,077 Active 2038-12-07 US11512288B2 (en) | 2016-08-24 | 2017-08-24 | Methods and kits for cell activation |
Country Status (5)
Country | Link |
---|---|
US (2) | US10294454B2 (en) |
EP (1) | EP3504323A1 (en) |
JP (1) | JP7043114B2 (en) |
CN (1) | CN109563484A (en) |
WO (1) | WO2018039400A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11512288B2 (en) | 2016-08-24 | 2022-11-29 | Global Life Sciences Solutions Usa Llc | Methods and kits for cell activation |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201820444D0 (en) * | 2018-12-14 | 2019-01-30 | Adaptimmune Ltd | Marker for T cell expansion |
CN110184239B (en) * | 2019-06-12 | 2021-04-06 | 蓝莲(杭州)生物科技有限公司 | Activated T lymphocyte culture solution and preparation method of activated T lymphocyte |
Family Cites Families (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3825615A1 (en) | 1988-07-28 | 1990-02-01 | Behringwerke Ag | ANTIGENT CONSTRUCTS OF "MAJOR HISTOCOMPATIBILITY COMPLEX" CLASS I ANTIGENS WITH SPECIFIC CARRIER MOLECULES, THEIR PRODUCTION AND USE |
US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
US7479269B2 (en) * | 1988-11-23 | 2009-01-20 | Genetics Institute, Llc | Methods for selectively enriching TH1 and TH2 cells |
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
JP2618497B2 (en) | 1989-10-03 | 1997-06-11 | 鐘淵化学工業株式会社 | Tumor-damaging cell inducer and tumor-damaging cell induction device |
US6197298B1 (en) | 1991-04-19 | 2001-03-06 | Tanox, Inc. | Modified binding molecules specific for T lymphocytes and their use as in vivo immune modulators in animals |
US6106835A (en) | 1991-04-19 | 2000-08-22 | Tanox, Inc. | Modified binding molecules specific for T or B lymphocytes and their use as in vivo immune modulators |
CA2065658A1 (en) | 1991-04-19 | 1992-10-20 | Tse-Wen Chang | Conjugates of liposomes or microbeads and antibodies specific for t lymphocytes and their use in vivo immune modulators |
US5872222A (en) | 1991-04-19 | 1999-02-16 | Tanox Biosystems, Inc. | Conjugates of polymers and antibodies specific for T lymphocytes, and their use as adjuvants |
US6129916A (en) | 1991-04-19 | 2000-10-10 | Tanox, Inc. | Method of Increasing activation on proliferation of T cells using antibody-microbead conjugates |
DE4237113B4 (en) | 1992-11-03 | 2006-10-12 | "Iba Gmbh" | Peptides and their fusion proteins, expression vector and method of producing a fusion protein |
WO1994012196A1 (en) | 1992-11-25 | 1994-06-09 | Tanox Biosystems, Inc. | Conjugates and constructs including anti-cd28 and anti-cd3 binding molecules |
EP0678034B1 (en) | 1993-01-11 | 1999-05-26 | Dana Farber Cancer Institute | Inducing cytotoxic t lymphocyte responses |
DK0700430T3 (en) | 1993-06-04 | 2005-08-15 | Us Navy | Methods to selectively stimulate proliferation of T cells |
CA2164646A1 (en) | 1993-06-11 | 1994-12-22 | Wade E. Bolton | Anti-cd3 antibody-aminodextran conjugates for induction of t-cell activation and proliferation |
US5635602A (en) | 1993-08-13 | 1997-06-03 | The Regents Of The University Of California | Design and synthesis of bispecific DNA-antibody conjugates |
US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
EP0764203A1 (en) | 1994-06-03 | 1997-03-26 | THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE NAVY | Methods for selectively stimulating proliferation of t cells |
US7074904B2 (en) | 1994-07-29 | 2006-07-11 | Altor Bioscience Corporation | MHC complexes and uses thereof |
CA2214649C (en) | 1995-03-08 | 2007-06-12 | Zeling Cai | Antigen presenting system and methods for activation of t-cells |
US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
JP4031033B2 (en) | 1995-05-04 | 2008-01-09 | アメリカ合衆国 | Improved T cell transfection method |
US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
NZ331688A (en) | 1996-03-28 | 2000-02-28 | Univ Johns Hopkins | Soluble divalent and multivalent heterodimeric analogs of proteins |
US7973137B1 (en) | 1996-03-28 | 2011-07-05 | Johns Hopkins University | Cell compositions comprising molecular complexes that modify immune responses |
US6458354B1 (en) | 1996-03-28 | 2002-10-01 | The Johns Hopkins University | Molecular complexes which modify immune responses |
ES2277358T3 (en) | 1996-09-06 | 2007-07-01 | Ortho-Mcneil Pharmaceutical, Inc. | PURIFICATION OF ANTIGEN T SPECIFIC CELLS. |
DE19641876B4 (en) | 1996-10-10 | 2011-09-29 | Iba Gmbh | streptavidin muteins |
US6077833A (en) | 1996-12-31 | 2000-06-20 | Isis Pharmaceuticals, Inc. | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
US7927595B1 (en) | 1997-02-21 | 2011-04-19 | The United States Of America As Represented By The Secretary Of The Navy | Methods for downregulating CCR5 in T cells with anti-CD3 antibodies and anti-CD28 antibodies |
US6268411B1 (en) | 1997-09-11 | 2001-07-31 | The Johns Hopkins University | Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses |
FR2766205B1 (en) | 1997-07-16 | 2002-08-30 | Inst Nat Sante Rech Med | NOVEL METHOD FOR SENSITIZING ANTIGEN PRESENTING CELLS AND NOVEL MEANS FOR IMPLEMENTING THE METHOD |
US6248564B1 (en) | 1997-08-29 | 2001-06-19 | Harvard University | Mutant MHC class I molecules |
AU741130B2 (en) | 1997-09-16 | 2001-11-22 | Oregon Health Sciences University | Recombinant MHC molecules useful for manipulation of antigen-specific T-cells |
US6232445B1 (en) | 1997-10-29 | 2001-05-15 | Sunol Molecular Corporation | Soluble MHC complexes and methods of use thereof |
ES2279600T3 (en) | 1998-03-12 | 2007-08-16 | Miltenyi Biotec Gmbh | MICROCOLUMN SYSTEM FOR MAGNETIC SEPARATION. |
US20020051783A1 (en) | 1998-06-05 | 2002-05-02 | Savage Philip Michael | Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class I molecule and an attaching means |
GB2339782A (en) | 1998-06-05 | 2000-02-09 | Philip Michael Savage | Chimeric protein complexes comprising HLA class I antigens |
US7521197B2 (en) | 1998-06-05 | 2009-04-21 | Alexis Biotech Limited | Method for producing cytotoxic T-cells |
US7264965B2 (en) | 1998-06-05 | 2007-09-04 | Alexis Biotech Limited | Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class I molecule and an attaching means |
US6787154B2 (en) | 1998-10-20 | 2004-09-07 | Salvatore Albani | Artificial antigen presenting cells |
DK1123086T3 (en) | 1998-10-20 | 2010-06-14 | Androclus Technologies S R L I | Artificial antigen-specific cells and associated methods |
US6590076B1 (en) | 1999-04-02 | 2003-07-08 | Corixa Corporation | Compositions for the treatment and diagnosis of breast cancer and methods for their use |
US7541184B2 (en) | 2000-02-24 | 2009-06-02 | Invitrogen Corporation | Activation and expansion of cells |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
MXPA02008265A (en) | 2000-02-24 | 2004-09-10 | Xcyte Therapies Inc | Simultaneous stimulation and concentration of cells. |
US20030235908A1 (en) | 2000-02-24 | 2003-12-25 | Xcyte Therapies, Inc. | Activation and expansion of cells |
US20030119185A1 (en) | 2000-02-24 | 2003-06-26 | Xcyte Therapies, Inc. | Activation and expansion of cells |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
EP1526171A1 (en) | 2000-02-24 | 2005-04-27 | Xcyte Therapies, Inc | Simultaneous stimulation and concentration of cells |
US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
EP1330516B1 (en) | 2000-11-03 | 2007-01-17 | The Regents Of The University Of Michigan | Surface transfection and expression procedure |
US6902933B2 (en) | 2000-11-03 | 2005-06-07 | Regents Of The University Of Michigan | Surface transfection and expression procedure |
US6897067B2 (en) | 2000-11-03 | 2005-05-24 | Regents Of The University Of Michigan | Surface transfection and expression procedure |
EP1227321A1 (en) | 2000-12-28 | 2002-07-31 | Institut für Bioanalytik GmbH | Reversible MHC multimer staining for functional purification of antigen-specific T cells |
DE10113776B4 (en) | 2001-03-21 | 2012-08-09 | "Iba Gmbh" | Isolated streptavidin-binding, competitively elutable peptide, this comprehensive fusion peptide, nucleic acid coding therefor, expression vector, methods for producing a recombinant fusion protein and methods for detecting and / or obtaining the fusion protein |
US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
AU2003202908A1 (en) | 2002-01-03 | 2003-07-24 | The Trustees Of The University Of Pennsylvania | Activation and expansion of t-cells using an engineered multivalent signaling platform |
AU2003216436A1 (en) | 2002-02-08 | 2003-09-02 | Life Technologies Corporation | Compositions and methods for restoring immune responsiveness in patients with immunological defects |
CN100379852C (en) * | 2002-02-08 | 2008-04-09 | 埃克斯西特治疗公司 | Compositions and methods for restoring immune responsiveness in patients with immunological defects |
US20040175373A1 (en) | 2002-06-28 | 2004-09-09 | Xcyte Therapies, Inc. | Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
US20050084967A1 (en) | 2002-06-28 | 2005-04-21 | Xcyte Therapies, Inc. | Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
WO2004003142A2 (en) | 2002-06-28 | 2004-01-08 | Xcyte Therapies, Inc. | Compositions and methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
JP5068931B2 (en) | 2002-07-12 | 2012-11-07 | ザ ジョンズ ホプキンス ユニバーシティー | Reagents and methods for binding to lymphocyte receptors of unique clonal traits |
GB2392158B (en) | 2002-08-21 | 2005-02-16 | Proimmune Ltd | Chimeric MHC protein and oligomer thereof |
CA2525519A1 (en) | 2003-05-08 | 2004-12-02 | Xcyte Therapies, Inc. | Generation and isolation of antigen-specific t cells |
US7402431B2 (en) | 2004-03-01 | 2008-07-22 | Immunovative Therapies, Ltd. | T-cell therapy formulation |
US7435592B2 (en) | 2003-05-13 | 2008-10-14 | Immunovative Therapies, Ltd. | Compositions for allogeneic cell therapy |
WO2005049085A1 (en) | 2003-11-18 | 2005-06-02 | Valeocyte Therapies Llc | Use of soluble complexes to facilitate cell activation |
US20050175583A1 (en) | 2003-12-02 | 2005-08-11 | Lawrence Tamarkin | Methods and compositions for the production of monoclonal antibodies |
US7592431B2 (en) | 2004-02-26 | 2009-09-22 | Immunovative Therapies, Ltd. | Biodegradable T-cell Activation device |
US7678572B2 (en) | 2004-02-26 | 2010-03-16 | Immunovative Therapies, Ltd. | Methods for preparing T-cells for cell therapy |
DE502004010393D1 (en) | 2004-03-04 | 2009-12-31 | Leukocare Gmbh | Leukocyte stimulation matrix |
GB2422834B8 (en) | 2005-02-04 | 2007-01-04 | Proimmune Ltd | MHC oligomer and method of making the same |
JP2006345852A (en) * | 2005-06-16 | 2006-12-28 | Virxsys Corp | Antibody conjugate |
GB0603081D0 (en) | 2006-02-15 | 2006-03-29 | Dynal Biotech Asa Oslo | Method |
GB2442048B (en) | 2006-07-25 | 2009-09-30 | Proimmune Ltd | Biotinylated MHC complexes and their uses |
CA2665568C (en) | 2006-10-04 | 2018-01-09 | Janssen Pharmaceutica, N.V. | Preparation of inactivated artificial antigen presenting cells and their use in cell therapies |
WO2008116468A2 (en) | 2007-03-26 | 2008-10-02 | Dako Denmark A/S | Mhc peptide complexes and uses thereof in infectious diseases |
WO2009005552A2 (en) | 2007-03-29 | 2009-01-08 | Epitype Corporation | Methods and compositions for multivalent binding and methods for manufacture of rapid diagnostic tests |
US8629098B2 (en) | 2008-01-15 | 2014-01-14 | Yale University | Compositions and methods for adoptive and active immunotherapy |
US8658178B2 (en) | 2008-03-19 | 2014-02-25 | Yale University | Carbon nanotube compositions and methods of use thereof |
WO2010037395A2 (en) | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
WO2011050000A2 (en) | 2009-10-20 | 2011-04-28 | The Regents Of The University Of California | Single molecule nucleic acid nanoparticles |
GB201002730D0 (en) | 2010-02-18 | 2010-04-07 | Uni I Oslo | Product |
WO2012024695A1 (en) | 2010-08-20 | 2012-02-23 | Life Technologies Corporation | Magnetic beads having surface glycoconjugates and use thereof |
WO2012044999A2 (en) | 2010-10-01 | 2012-04-05 | Ludwig Institute For Cancer Research Ltd. | Reversible protein multimers, methods for their production and use |
CN103797028B (en) | 2011-07-18 | 2017-08-25 | Iba 股份有限公司 | Make the method for the reversible dyeing of target cell |
US8834889B2 (en) | 2011-08-29 | 2014-09-16 | National Tsing Hua University | Antigen presenting composition and use thereof |
JP2015500296A (en) | 2011-12-09 | 2015-01-05 | ザ・ジョンズ・ホプキンス・ユニバーシティ | Artificial antigen-presenting cells with a defined dynamic shape |
WO2013109568A1 (en) | 2012-01-17 | 2013-07-25 | Croda, Inc. | Seal swell additive |
CN106940268B (en) | 2012-02-23 | 2021-09-21 | 朱诺治疗有限公司 | Chromatographic separation of cells and other complex biological materials |
EP2711418B1 (en) * | 2012-09-25 | 2017-08-23 | Miltenyi Biotec GmbH | Method for polyclonal stimulation of T cells by flexible nanomatrices |
WO2014076277A1 (en) | 2012-11-16 | 2014-05-22 | Iba Gmbh | Streptavidin muteins and methods of using them |
ES2820729T3 (en) | 2013-02-15 | 2021-04-22 | Univ Johns Hopkins | Antigen-specific T-cell redirectors |
JP6501270B2 (en) | 2013-03-14 | 2019-04-17 | ザ カリフォルニア インスティテュート フォー バイオメディカル リサーチ | Targeting agent-antibody conjugates and uses thereof |
CN105431523B (en) | 2013-03-14 | 2020-08-21 | 约翰·霍普金斯大学 | Nanoscale artificial antigen presenting cells |
BR112015032277B1 (en) | 2013-06-24 | 2020-12-01 | Neximmune | antigen presentation complex, its use, and composition |
ES2612918T3 (en) * | 2013-07-10 | 2017-05-19 | Miltenyi Biotec Gmbh | Method to induce the proliferation of natural killer cells by mobile nanomatrices |
JP5799058B2 (en) | 2013-07-30 | 2015-10-21 | 三桜工業株式会社 | Negative pressure pump and cylinder head cover |
CN116656605A (en) | 2014-04-16 | 2023-08-29 | 朱诺治疗有限公司 | Methods, kits and devices for expanding cell populations |
WO2016033690A1 (en) * | 2014-09-04 | 2016-03-10 | Stemcell Technologies Inc. | Soluble antibody complexes for t cell or nk cell activation and expansion |
US10294454B2 (en) | 2016-08-24 | 2019-05-21 | General Electric Company | Methods and kits for cell activation |
-
2016
- 2016-08-24 US US15/245,584 patent/US10294454B2/en active Active
-
2017
- 2017-08-24 EP EP17769141.7A patent/EP3504323A1/en active Pending
- 2017-08-24 WO PCT/US2017/048306 patent/WO2018039400A1/en unknown
- 2017-08-24 JP JP2019510693A patent/JP7043114B2/en active Active
- 2017-08-24 CN CN201780051673.1A patent/CN109563484A/en active Pending
- 2017-08-24 US US16/339,077 patent/US11512288B2/en active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11512288B2 (en) | 2016-08-24 | 2022-11-29 | Global Life Sciences Solutions Usa Llc | Methods and kits for cell activation |
Also Published As
Publication number | Publication date |
---|---|
JP2019534684A (en) | 2019-12-05 |
EP3504323A1 (en) | 2019-07-03 |
CN109563484A (en) | 2019-04-02 |
WO2018039400A1 (en) | 2018-03-01 |
US10294454B2 (en) | 2019-05-21 |
US20200181572A1 (en) | 2020-06-11 |
JP7043114B2 (en) | 2022-03-29 |
US11512288B2 (en) | 2022-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20240084287A1 (en) | Single cell cellular component enrichment from barcoded sequencing libraries | |
AU2020230334A1 (en) | Compositions and methods for immunooncology | |
CA3126699A1 (en) | Modified immune cells having enhanced anti-neoplasia activity and immunosuppression resistance | |
JP2018512162A5 (en) | ||
CA3151690A1 (en) | Genetically-edited immune cells and methods of therapy | |
JP2004024264A (en) | ANTISENSE-OLIGONUCLEOTIDES FOR TREATMENT OF IMMUNOSUPPRESSIVE EFFECTS OF TRANSFORMING GROWTH FACTOR-beta (TGF-beta) | |
US10294454B2 (en) | Methods and kits for cell activation | |
Cardle et al. | Biomaterials in chimeric antigen receptor T-cell process development | |
CA3168932A1 (en) | Methods for activation and expansion of tumor infiltrating lymphocytes | |
JP2021518760A (en) | Modification of loci in the immune-related genome using paired CRISPR nickaseribonuclear proteins | |
US20240024478A1 (en) | Compositions and Methods for Reducing HLA-A in a Cell | |
US20210062248A1 (en) | Methods of performing guide-seq on primary human t cells | |
IL303505A (en) | Compositions and methods for reducing mhc class ii in a cell | |
CA3183129A1 (en) | Rna scaffolds | |
US20240139323A1 (en) | Compositions and Methods for Genetically Modifying CIITA in a Cell | |
US20210171908A1 (en) | Allogeneic t-cells and methods for production thereof | |
RU2771624C2 (en) | Compositions and methods for immune oncology | |
WO2023240218A1 (en) | Methods for detecting genomic abnormalities in cells | |
KR20230044537A (en) | Compositions and methods for engineering and selecting CAR T cells with desired phenotypes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: GENERAL ELECTRIC COMPANY, NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KOVACS, ERNEST WILLIAM;SOOD, ANUP;SMITH, REGINALD DONOVAN;AND OTHERS;SIGNING DATES FROM 20160729 TO 20160824;REEL/FRAME:039525/0388 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
AS | Assignment |
Owner name: GENERAL ELECTRIC COMPANY, NEW YORK Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE FIFTH ASSIGNOR CHADHURI, PADMAPARNA PREVIOUSLY RECORDED ON REEL 039525 FRAME 0388. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNORS:KOVACS, ERNEST WILLIAM;SOOD, ANUP;SMITH, REGINALD DONOVAN;AND OTHERS;SIGNING DATES FROM 20160729 TO 20190320;REEL/FRAME:050719/0263 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
AS | Assignment |
Owner name: GLOBAL LIFE SCIENCES SOLUTIONS USA LLC, MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GENERAL ELECTRIC COMPANY;REEL/FRAME:053966/0133 Effective date: 20200320 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 4 |